<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71142</article-id><article-id pub-id-type="doi">10.7554/eLife.71142</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Proteolysis of fibrillin-2 microfibrils is essential for normal skeletal development</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-244270"><name><surname>Mead</surname><given-names>Timothy J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1891-3652</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244271"><name><surname>Martin</surname><given-names>Daniel R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244273"><name><surname>Wang</surname><given-names>Lauren W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244274"><name><surname>Cain</surname><given-names>Stuart A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244275"><name><surname>Gulec</surname><given-names>Cagri</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244276"><name><surname>Cahill</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244272"><name><surname>Mauch</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225783"><name><surname>Reinhardt</surname><given-names>Dieter</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61394"><name><surname>Lo</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-21759"><name><surname>Baldock</surname><given-names>Clair</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-66542"><name><surname>Apte</surname><given-names>Suneel S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8441-1226</contrib-id><email>aptes@ccf.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Department of Biomedical Engineering and Musculoskeletal Research Center, Cleveland Clinic Lerner Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland, Ohio</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04rrkhs81</institution-id><institution>Division of Cell-Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre</institution></institution-wrap><addr-line><named-content content-type="city">Manchester</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>Department of Developmental Biology, University of Pittsburgh School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh, Pennsylvania</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>Faculty of Medicine and Health Sciences and Faculty of Dental Medicine and Oral Health Sciences, McGill University</institution></institution-wrap><addr-line><named-content content-type="city">Montreal</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schipani</surname><given-names>Ernestina</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>University of Pennsylvania</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cheah</surname><given-names>Kathryn Song Eng</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>03</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e71142</elocation-id><history><date date-type="received" iso-8601-date="2021-06-10"><day>10</day><month>06</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-04-13"><day>13</day><month>04</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-02-03"><day>03</day><month>02</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.02.03.429587"/></event></pub-history><permissions><copyright-statement>© 2022, Mead et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Mead et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71142-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-71142-figures-v1.pdf"/><abstract><p>The embryonic extracellular matrix (ECM) undergoes transition to mature ECM as development progresses, yet few mechanisms ensuring ECM proteostasis during this period are known. Fibrillin microfibrils are macromolecular ECM complexes serving structural and regulatory roles. In mice, <italic>Fbn1</italic> and <italic>Fbn2,</italic> encoding the major microfibrillar components, are strongly expressed during embryogenesis, but fibrillin-1 is the major component observed in adult tissue microfibrils. Here, analysis of <italic>Adamts6</italic> and <italic>Adamts10</italic> mutant mouse embryos, lacking these homologous secreted metalloproteases individually and in combination, along with in vitro analysis of microfibrils, measurement of ADAMTS6-fibrillin affinities and N-terminomics discovery of ADAMTS6-cleaved sites, identifies a proteostatic mechanism contributing to postnatal fibrillin-2 reduction and fibrillin-1 dominance. The lack of ADAMTS6, alone and in combination with ADAMTS10 led to excess fibrillin-2 in perichondrium, with impaired skeletal development defined by a drastic reduction of aggrecan and cartilage link protein, impaired BMP signaling in cartilage, and increased GDF5 sequestration in fibrillin-2-rich tissue. Although ADAMTS6 cleaves fibrillin-1 and fibrillin-2 as well as fibronectin, which provides the initial scaffold for microfibril assembly, primacy of the protease-substrate relationship between ADAMTS6 and fibrillin-2 was unequivocally established by reversal of the defects in <italic>Adamts6</italic><sup>-/-</sup> embryos by genetic reduction of <italic>Fbn2</italic>, but not <italic>Fbn1</italic>.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>extracellular matrix</kwd><kwd>Protease</kwd><kwd>ADAMTS</kwd><kwd>proteolysis</kwd><kwd>fibrillin</kwd><kwd>skeletal development</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>17DIA33820024</award-id><principal-award-recipient><name><surname>Apte</surname><given-names>Suneel S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F32AR063548</award-id><principal-award-recipient><name><surname>Mead</surname><given-names>Timothy J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>RO1HL156987</award-id><principal-award-recipient><name><surname>Mead</surname><given-names>Timothy J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>PJT-162099</award-id><principal-award-recipient><name><surname>Reinhardt</surname><given-names>Dieter</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Marfan Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Reinhardt</surname><given-names>Dieter</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>203128/Z/16/Z</award-id><principal-award-recipient><name><surname>Baldock</surname><given-names>Clair</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/R008221/1</award-id><principal-award-recipient><name><surname>Baldock</surname><given-names>Clair</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Paul G Allen Frontiers Group</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Apte</surname><given-names>Suneel S</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Proteolytic cleavage of the extracellular matrix glycoprotein fibrillin-2 by the secreted metalloprotease ADAMTS6 influences skeletal development by modulating fibrillin microfibril abundance and GDF5/BMP signaling, illustrating the crucial role of extracellular matrix proteostatic mechanisms in growth factor regulation during morphogenesis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In addition to proliferation and differentiation of resident cells, proper tissue and organ development, structure and function require an appropriate extracellular matrix (ECM). How ECM architecture and stoichiometry are maintained and adjusted in coordination with the dynamic tissue changes during morphogenesis and transition to the adult organism is unknown. Ontogenetically, the earliest cell collectives formed sheets and tubes with a well-established basement membrane that provided a substrate for cell migration and adhesive inputs that determined cell polarity. Expansion of ECM-encoding genes enabled formation of a complex interstitial matrix that promoted evolution of ever more complex organisms (<xref ref-type="bibr" rid="bib35">Huxley-Jones et al., 2007b</xref>), but presented a challenge for remodeling of the increasingly diverse ECM repertoire within complex ECM assemblies, which appears to have been met by expansion of secreted and cell-surface protease genes (<xref ref-type="bibr" rid="bib33">Huxley-Jones et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Huxley-Jones et al., 2007a</xref>). For example, there are 19 ADAMTS proteases present in mammals compared to only 2 in the fruitfly and the majority cleave ECM molecules (<xref ref-type="bibr" rid="bib18">Dubail and Apte, 2015</xref>; <xref ref-type="bibr" rid="bib52">Mead and Apte, 2018a</xref>). However, which specific ECM molecules and supramolecular assemblies are targets of the individual proteases, the specific contexts they operate in, and relationships between individual proteases are poorly understood. The embryonic interstitial ECM is highly hydrated owing to abundant macromolecular hyaluronan (HA)-proteoglycan aggregates whereas fibrillar components, primarily collagens and elastin, dominate juvenile and adult ECM composition and provide structural resilience needed for the greater mechanical demands imposed by postnatal life. Beyond structural roles, ECM sequesters and regulates the activity of morphogens and growth factors (<xref ref-type="bibr" rid="bib69">Ramirez et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Thomson et al., 2019</xref>), and ECM proteolysis can generate bioactive fragments, termed matrikines (<xref ref-type="bibr" rid="bib70">Ricard-Blum and Vallet, 2019</xref>).</p><p>Fibrillin microfibrils have a crucial role in tissue development and homeostasis by providing mechanical stability and limited elasticity to tissues and/or regulating growth factors of the TGFβ superfamily, including bone morphogenetic proteins (BMPs) and growth/differentiation factors (GDFs) (<xref ref-type="bibr" rid="bib69">Ramirez et al., 2018</xref>; <xref ref-type="bibr" rid="bib82">Thomson et al., 2019</xref>), along with a key role in elastic fiber assembly (<xref ref-type="bibr" rid="bib79">Shin and Yanagisawa, 2019</xref>; <xref ref-type="bibr" rid="bib42">Kozel and Mecham, 2019</xref>). Fibrillins are large, cysteine-rich glycoproteins containing many epidermal growth factor (EGF)-like repeats. Of the three fibrillin isoforms, fibrillin-2 and fibrillin-3 (in humans) are primarily expressed during embryogenesis (<xref ref-type="bibr" rid="bib73">Sabatier et al., 2011</xref>; <xref ref-type="bibr" rid="bib89">Zhang et al., 1994</xref>; <xref ref-type="bibr" rid="bib90">Zhang et al., 1995</xref>). The gene encoding fibrillin-3 is inactivated in mice (<xref ref-type="bibr" rid="bib13">Corson et al., 2004</xref>), providing a simpler scenario than in humans for investigating developmental regulation of microfibril composition and the role of proteolytic turnover therein. Among numerous gene mutations affecting the skeleton (<xref ref-type="bibr" rid="bib88">Yip et al., 2019</xref>), <italic>FBN1</italic> and <italic>FBN2</italic> mutations cause Marfan syndrome and congenital contractural arachnodactyly, respectively, in humans (<xref ref-type="bibr" rid="bib71">Robinson et al., 2006</xref>). Despite overlapping features such as skeletal overgrowth and poor muscular development, each disorder mainly has distinct manifestations, indicating that fibrillin isoforms either contribute specific mechanical or regulatory properties to microfibrils, have a tissue-specific function, or form distinct ECM networks. Severe cardiovascular manifestations, especially aortic root and ascending aorta aneurysms, which are potentially lethal, as well as ocular manifestations, occur frequently in Marfan syndrome, but neither is typically associated with <italic>FBN2</italic> mutations (<xref ref-type="bibr" rid="bib71">Robinson et al., 2006</xref>). In mice, <italic>Fbn2</italic> deficiency affects myogenesis and distal limb patterning, indicating a key role for fibrillin-2 in BMP/GDF regulation (<xref ref-type="bibr" rid="bib1">Arteaga-Solis et al., 2001</xref>; <xref ref-type="bibr" rid="bib78">Sengle et al., 2015</xref>).</p><p>Fibrillin microfibrils can be homotypic or heterotypic (<xref ref-type="bibr" rid="bib10">Charbonneau et al., 2003</xref>; <xref ref-type="bibr" rid="bib48">Marson et al., 2005</xref>; <xref ref-type="bibr" rid="bib46">Lin et al., 2002</xref>), but since each fibrillin appears to have distinct roles in vivo as well as in vitro (<xref ref-type="bibr" rid="bib65">Nistala et al., 2010</xref>), intriguing questions are how the correct stoichiometry of the two fibrillins is maintained, and the impact of excess fibrillin microfibrils or altered fibrillin stoichiometry on biological systems. Here, analysis of mouse mutants of the homologous secreted metalloproteases ADAMTS6 and ADAMTS10 has identified a transcriptionally adapted system for proteostasis of fibrillin microfibrils, defined the impact of ADAMTS6 and ADAMTS10 deficiency on skeletal development, uncovered and demonstrated the importance of a specific protease-substrate relationship between these proteases and fibrillin-2 relevant to skeletal development and unearthed an impact on limb growth factor sequestration.</p><p>ADAMTS10 has established relevance to skeletal dysplasias. Recessive <italic>ADAMTS10</italic> mutations lead to an acromelic dysplasia, Weill-Marchesani syndrome 1 (WMS1) (<xref ref-type="bibr" rid="bib14">Dagoneau et al., 2004</xref>), whereas dominant <italic>FBN1</italic> mutations cause a phenotypically similar disorder, WMS2 (<xref ref-type="bibr" rid="bib22">Faivre et al., 2003b</xref>), suggesting a functional relationship between ADAMTS10 and fibrillin-1 (<xref ref-type="bibr" rid="bib31">Hubmacher and Apte, 2015</xref>; <xref ref-type="bibr" rid="bib37">Karoulias et al., 2020</xref>). Indeed, ADAMTS10 bound fibrillin-1 directly and accelerated fibrillin-1 microfibril biogenesis in vitro, but cleaved fibrillin-1 inefficiently (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Kutz et al., 2011</xref>). Mice with <italic>Adamts10</italic> inactivation or homozygous for a human WMS-causing <italic>ADAMTS10</italic> mutation had mildly impaired long bone growth and increased muscle mass along with reduced fibrillin-1 staining in skeletal muscle and persistence of fibrillin-2 microfibrils in skeletal muscle and the eye (<xref ref-type="bibr" rid="bib59">Mularczyk et al., 2018</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2019a</xref>). ADAMTS10 undergoes inefficient processing by furin, typically a prerequisite for activation of ADAMTS proteases (<xref ref-type="bibr" rid="bib43">Kutz et al., 2011</xref>). However, ADAMTS10, when constitutively activated by optimizing its furin processing site, can proteolytically process fibrillin-2 (<xref ref-type="bibr" rid="bib85">Wang et al., 2019a</xref>). In contrast to ADAMTS10, ADAMTS6 is efficiently processed by furin (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>; <xref ref-type="bibr" rid="bib67">Prins et al., 2018</xref>), but its activity and functional relationship with ADAMTS10 are poorly characterized, although it is known to cleave latent TGFβ-binding protein 1, a fibrillin relative, as well as cell-surface heparan sulfate proteoglycans (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>).</p><p>Since ADAMTS proteases cooperate in several physiological contexts where they are co-expressed (<xref ref-type="bibr" rid="bib17">Dubail et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Enomoto et al., 2010</xref>; <xref ref-type="bibr" rid="bib50">McCulloch et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Mead et al., 2018b</xref>; <xref ref-type="bibr" rid="bib62">Nandadasa et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Nandadasa et al., 2015</xref>) and their pairwise homology suggests the possibility of transcriptional adaptation (<xref ref-type="bibr" rid="bib19">El-Brolosy et al., 2019</xref>; <xref ref-type="bibr" rid="bib81">Sztal and Stainier, 2020</xref>), which has not been systematically investigated in this family, we investigated the impact of single or combined inactivation of <italic>Adamts6</italic> and <italic>Adamts10</italic> on mouse skeletal development, and defined the underlying mechanisms. The findings provide intriguing new insights into fibrillin microfibril proteostasis and mechanisms regulating skeletal development.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Transcriptional adaptation of <italic>Adamts6</italic> and <italic>Adamts10</italic></title><p>Previous work had suggested that knockdown of <italic>ADAMTS10</italic> in cultured human ARPE-19A cells increased <italic>ADAMTS6</italic> expression (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>). To investigate the possibility that germline mutations of either mouse gene affected expression of the other, <italic>Adamts6</italic> and <italic>Adamts10</italic> mRNA levels were measured in limbs, heart and lungs of <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts10</italic><sup>-/-</sup> mice. qRT-PCR analysis showed that <italic>Adamts6</italic> mRNA was reduced in limb and lung with respect to wild type levels in <italic>Adamts6-</italic>mutant mice [which have a missense Ser<sup>149</sup>Arg mutation that abrogates protein secretion, essentially comprising a knockout (<xref ref-type="bibr" rid="bib67">Prins et al., 2018</xref>)], but was consistently increased in <italic>Adamts10</italic><sup>-/-</sup> tissues (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). <italic>Adamts10</italic> mRNA was undetectable in <italic>Adamts10</italic><sup>-/-</sup> mice (which have an intragenic IRES-<italic>lacZ</italic> insertion that disrupts mRNA continuity), and increased in <italic>Adamts6</italic><sup>-/-</sup> tissues (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Thus, each gene shows reciprocal increased expression when either is inactivated, suggestive of transcriptional adaptation. In contrast, mRNA for <italic>Adamts17</italic>, also linked to WMS (<xref ref-type="bibr" rid="bib58">Morales et al., 2009</xref>), and its homolog <italic>Adamts19</italic> were unchanged in <italic>Adamts6</italic>- or <italic>Adamts10</italic>-deficient tissues (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We also asked whether ADAMTS6 and ADAMTS10 cleaved each other. Neither ADAMTS10 nor furin-optimized ADAMTS10 cleaved ADAMTS6 and ADAMTS6 did not cleave ADAMTS10 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). These finding raised the possibility that <italic>Adamts10</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup> phenotypes could have been buffered by a compensating increase in the homologous mRNA and resulting protease activity. Furthermore, these genes could have cooperative functions, such as were previously identified in combined mutants of other homologous ADAMTS proteases (<xref ref-type="bibr" rid="bib53">Mead et al., 2018b</xref>; <xref ref-type="bibr" rid="bib62">Nandadasa et al., 2019</xref>). Both possibilities were addressed by analyzing the role of ADAMTS6 in skeletal development, characterization of the skeletal defects in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> mice and determination of ADAMTS6 activity in regard to fibrillins, none of which were previously undertaken. Combinations of the two mutant alleles were obtained by interbreeding, since each gene is on a distinct mouse chromosome.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>ADAMTS6 and ADAMTS10 are subject to transcriptional adaptation and cooperate in skeletal development.</title><p>(<bold>A</bold>) qRT-PCR analysis of <italic>Adamts6</italic> and <italic>Adamts10</italic> mRNA levels in wild type, <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts10</italic><sup>-/-</sup> limb, heart and lung show that <italic>Adamts6</italic> mRNA is elevated in <italic>Adamts10</italic><sup>-/-</sup> limb, heart and lung and <italic>Adamts10</italic> mRNA is elevated in <italic>Adamts6</italic><sup>-/-</sup> tissues. n ≥ 6. Error bars represent ± SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, Student t-test. There is no change in <italic>Adamts17</italic> or <italic>Adamts19</italic> mRNA levels in the <italic>Adamts6</italic> or <italic>Adamts10</italic>-deficent limbs. (<bold>B, C</bold>) E14.5 (<bold>B</bold>) and E16.5 (<bold>C</bold>) alcian blue- and alizarin red-stained skeletons show severely short and under-ossified <italic>Adamts6</italic><sup>-/-</sup> hindlimb long bones (arrowheads) with severely distorted tibia and fibula (arrow). <italic>Adamts6</italic><sup>-/-</sup> forelimbs are not as severely affected as hindlimbs. (<bold>D</bold>) E18.5 <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> embryos have more severe hindlimb malformations (arrows) and shorter forelimbs and snout than <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts10</italic><sup>-/-</sup> embryos as well as mandibular hypoplasia (bracket), an omphalocele (asterisk) and widespread cutaneous hemorrhage (arrowhead). (<bold>E, F</bold>) Alcian blue- and alizarin red-stained <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> forelimbs (<bold>E</bold>) and hindlimbs (<bold>F</bold>) show unremodeled, thicker and shorter long bones (asterisks show thicker diaphysis; H, humerus; F, femur; U, ulna; R, radius; Tib, tibia; Fib, fibula) with angulated radius (arrow) and tibia (arrowhead). Note the unossified fibula in the E18.5 <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> hindlimb.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>ADAMTS6 and ADAMTS10 do not cleave each other.</title><p>(<bold>A</bold>) ADAMTS10 was co-transfected with ADAMTS6 or the catalytically inactive mutant ADAMTS6 EA. (<bold>B</bold>) Furin site-optimized ADAMTS10 (ADAMTS10-RRKR) was co-transfected with ADAMTS6 EA. No cleavage products of either ADAMTS6 or ADAMTS10 were seen.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Expected Mendelian ratios are observed in mouse crosses.</title><p>Mendelian ratios obtained from <italic>Adamts6</italic><sup>+/-</sup> intercrosses (<bold>A</bold>) and <italic>Adamts6</italic><sup>+/-</sup><italic>;Adamts10</italic><sup>+/-</sup> intercrosses at E18.5 (<bold>B</bold>) are shown. Observed and expected (in parentheses) genotype percentages are shown in the pie-charts. The actual number of mice generated is illustrated below the pie-charts.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Reduced crown-rump length and shorter limb skeletal elements in <italic>Adamts6</italic><sup>-/-</sup> embyros.</title><p>At E14.5 (<bold>A</bold>) and E16.5 (<bold>B</bold>), <italic>Adamts6</italic>-deficient embryos have reduced crown-rump length and shorter long bones as compared to wild type embryos. Crown-rump length, n = 4; bone length, n ≥ 6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Reduced crown-rump length and shorter limb skeletal elements in combined <italic>Adamts6</italic> and <italic>Adamts10</italic> alleles at E18.5.</title><p>(<bold>A</bold>) <italic>Adamts6</italic>- and <italic>Adamts10</italic>-deficient embryos and embryos with various combinations of alleles have reduced crown-rump length as compared to wild type embryos. (<bold>B</bold>) Embryos with various combinations of the <italic>Adamts6</italic>-mutant allele have shorter long bones than wild type, as shown. <italic>Adamts10</italic><sup>-/-</sup> long bones were not significantly shorter than those of wild type littermates. Crown-rump length, n ≥ 6; bone length, n ≥ 8. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Greater diaphyseal width in <italic>Adamts6</italic><sup>-/-</sup> long bones.</title><p>E18.5 <italic>Adamts6</italic>-deficient embryos have wider long bones than wild type embryos. n ≥ 6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp5-v1.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title>Delayed ossification and shorter femora in <italic>Adamts6</italic><sup>-/-</sup> embyros.</title><p>Alcian blue-stained sections show the primary ossification center in E14.5 wild type femur (lack of blue staining in the diaphysis). The primary center did not form until E16.5 in the <italic>Adamts6</italic><sup>-/-</sup> femur. n ≥ 4.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp6-v1.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 7.</label><caption><title>Angulation of the <italic>Adamts6</italic><sup>-/-</sup> distal tibia.</title><p>Alcian blue-stained sections revealed marked distal tibial angulation in <italic>Adamts6</italic><sup>-/-</sup> hindlimbs as early as E14.5, which persisted and contributed to a club-foot like appearance of the hindlimbs. n ≥ 4.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp7-v1.tif"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 8.</label><caption><title>Severely hypoplastic fibula in <italic>Adamts6</italic><sup>-/-</sup> embryos.</title><p>Alcian blue-stained sections revealed a delay in chondrocyte hypertrophy until E16.5 in <italic>Adamts6</italic><sup>-/-</sup> fibula whereas it occurred at E14.5 in wild type fibula. Similarily, ossification was delayed until E18.5 in <italic>Adamts6</italic><sup>-/-</sup> fibulae as opposed to E16.5 in wild type. n ≥ 4.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp8-v1.tif"/></fig><fig id="fig1s9" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 9.</label><caption><title>Decreased mineralization in <italic>Adamts6</italic>-deficent hindlimb long bones.</title><p>(<bold>A,B</bold>) E14.5 von Kossa-stained sections (<bold>A</bold>) quantified in (<bold>B</bold>) revealed reduced mineral deposition (black) in <italic>Adamts6</italic><sup>-/-</sup> hindlimb bones. Significant staining in the periosteum as well as in the center of the diaphysis was seen in wild type limb sections. Minimal staining was seen in <italic>Adamts6</italic><sup>-/-</sup> femur and tibial periosteum while mineralization was lacking entirely in the fibula. n ≥ 3. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. (<bold>C,D</bold>) Mineralization occurs in E18.5 <italic>Adamts6</italic><sup>-/-</sup> hindlimb bones, and although the primary ossific center is smaller, the perichondrial collar and hypertrophic zones show comparable mineralization.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp9-v1.tif"/></fig><fig id="fig1s10" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 10.</label><caption><title><italic>Adamts6</italic>-mutant embryos have a severely underdeveloped axial skeleton.</title><p>Alcian blue- and alizarin red -stained E18.5 axial skeleton and craniofacial preparations show that <italic>Adamts6<sup>-</sup></italic><sup>/-</sup> and <italic>Adamts6<sup>-</sup></italic><sup>/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> embryos have shortened, stout ribs (asterisks), shortened and disorganized manubrium and sternum (small arrows) (note the under-ossified/unossified xiphoid process (arrowheads)), smaller vertebral bodies (large arrows), and a smaller cranium with delayed mineralization of parietal bones (dashed white lines).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig1-figsupp10-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Severe skeletal malformations in <italic>Adamts6-</italic>deficient embryos are exacerbated by concurrent <italic>Adamts10</italic> inactivation</title><p>Analysis of the <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts10</italic><sup>-/-</sup> crosses showed that the mutant genotypes were recovered at the expected Mendelian ratio at the end of the embryonic period (E18.5) (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A, B</xref>). <italic>Adamts6</italic><sup>-/-</sup> embryos had severe reduction of crown to rump length, measured at E14.5, E16.5 and E18.5, which was also statistically significant in <italic>Adamts10</italic><sup>-/-</sup> mice at E18.5 (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A, B</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>). Whereas <italic>Adamts6</italic><sup>-/-</sup> forelimbs appeared shorter, <italic>Adamts6</italic><sup>-/-</sup> hindlimbs were severely short and internally rotated (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A, B</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>, <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Alizarin red- and alcian blue-stained skeletal preparations at embryonic day (E)14.5, when ossification is initiated, and at E16.5 and E18.5, by which time it is established, showed reduced ossification of <italic>Adamts6</italic><sup>-/-</sup> hindlimb distal long bones and deformation of all hindlimb segments (<xref ref-type="fig" rid="fig1">Figure 1B, C and F</xref>), most evident in the thicker tibia and angulated fibula (<xref ref-type="fig" rid="fig1">Figure 1B, C and F</xref>, arrows). <italic>Adamts6</italic><sup>-/-</sup> forelimbs demonstrated failure of diaphyseal remodeling (e.g. wider, tubular-appearing radius and ulna) and smaller ossific centers than wild type littermates after E14.5 (<xref ref-type="fig" rid="fig1">Figure 1B, C and E</xref>). Neither forelimbs nor hindlimbs showed skeletal patterning anomalies. In contrast to <italic>Adamts6</italic><sup>-/-</sup> embryos, <italic>Adamts10</italic><sup>-/-</sup> embryos had a morphologically normal appendicular skeleton without statistically significant shortening of individual long bones (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>; <xref ref-type="bibr" rid="bib59">Mularczyk et al., 2018</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2019a</xref>).</p><p>Histologic comparison of alcian blue-stained hindlimb long bone sections at daily intervals from E14.5-E18.5 showed delayed appearance of femoral and fibular primary ossific centers in <italic>Adamts6<sup>-</sup></italic><sup>/-</sup> embyros, with persistence of hypertrophic chondrocytes and delayed vascular invasion; in the tibia, the primary ossific center appeared on schedule, but was persistently smaller (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplements 6</xref>–<xref ref-type="fig" rid="fig1s8">8</xref>). The distal tibia and fibula showed pronounced angulation as early as E14.5, persisting through E18.5 (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplements 7</xref>–<xref ref-type="fig" rid="fig1s8">8</xref>). Mineral deposition, visualized by von Kossa staining at E14.5, was reduced in the perichondrium/periosteum as well as within the primary center hypertrophic zones in <italic>Adamts6</italic><sup>-/-</sup> femur and tibia and undetectable in the fibula as compared to control (<xref ref-type="fig" rid="fig1s9">Figure 1—figure supplement 9A, B</xref>), whereas by E18.5, mineralization was seen in each primary center (<xref ref-type="fig" rid="fig1s9">Figure 1—figure supplement 9C, D</xref>).</p><p>The axial and craniofacial skeleton were also abnormal in E18.5 <italic>Adamts6</italic><sup>-/-</sup> embryos, with shortened, tubular ribs, absence of sternal segmentation and under-ossified xiphoid processes (<xref ref-type="fig" rid="fig1s10">Figure 1—figure supplement 10</xref>). Additionally, their vertebral bodies were smaller in size with corresponding size reduction of all vertebral ossification centers. <italic>Adamts6</italic><sup>-/-</sup> craniofacial skeletons had reduced anterior-posterior and nasal-occipital dimensions, a corresponding reduction in size of individual elements, delayed ossification of parietal bones and wider anterior fontanelles (<xref ref-type="fig" rid="fig1s10">Figure 1—figure supplement 10</xref>).</p><p><italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> embryos demonstrated markedly more severe external anomalies than <italic>Adamts6</italic><sup>-/-</sup> mutants including subcutaneous hemorrhage, micrognathia and an omphalocele, along with more severe forelimb and hindlimb dysmorphology (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Skeletal preparations showed more severe hindlimb anomalies than in <italic>Adamts6</italic><sup>-/-</sup> mutants and appearance of forelimb abnormalities similar in degree of severity to <italic>Adamts6</italic><sup>-/-</sup> hindlimbs with externally evident shortening, the greatest reduction of nose-rump length among all genotypes and the shortest long bones among the generated genotypes (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). Fibular ossification was minimal, and the zeugopods showed pronounced tibio-fibular angulation (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The shortened and tubular ribs, vertebral bodies with smaller ossification centers, lack of xiphoid process ossification and poor ossification of cranial bones resulting in larger fontanelles, further demonstrated more severe impairment of axial and craniofacial skeletal development than in <italic>Adamts6</italic><sup>-/-</sup> embryos (<xref ref-type="fig" rid="fig1s10">Figure 1—figure supplement 10</xref>). Whereas inactivation of one <italic>Adamts6</italic> allele in <italic>Adamts10</italic><sup>-/-</sup> mice did not significantly worsen the observed dysmorphology and skeletal phenotype, <italic>Adamts10</italic> haploinsufficiency further reduced <italic>Adamts6</italic><sup>-/-</sup> crown to rump length and led to shorter femur, tibia, fibula, humerus, radius and ulna (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>).</p></sec><sec id="s2-3"><title><italic>Adamts6</italic> and <italic>Adamts10</italic> have overlapping expression in limb skeletal development</title><p>To follow up on prior publications showing strong expression of <italic>Adamts6</italic> in the heart and of <italic>Adamts10</italic> in multiple embryonic and adult tissues (<xref ref-type="bibr" rid="bib85">Wang et al., 2019a</xref>; <xref ref-type="bibr" rid="bib67">Prins et al., 2018</xref>; <xref ref-type="bibr" rid="bib80">Somerville et al., 2004</xref>) as well as immunohistochemical localization of ADAMTS10 in limb growth cartilage, perichondrium and muscle, we compared the spatial and temporal localization of their mRNAs during hindlimb development using RNAscope in situ hybridization. <italic>Adamts6</italic> and <italic>Adamts10</italic> exhibited overlapping expression in E13.5 resting and proliferating zone chondrocytes and perichondrium (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). At E14.5, when the first primary ossific centers are formed, both genes maintained strong expression in the perichondrium (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). They are expressed in the the knee joint mesenchyme, and <italic>Adamts6</italic> was strongly expressed in the patellar tendon (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Both genes were expressed in muscles and tendons around the hip, elbow, and ankle and in vertebral endplates (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Adamts6</italic> and <italic>Adamts10</italic> mRNAs show overlapping distribution in developing mouse limbs.</title><p>(<bold>A</bold>) RNAscope in situ hybridization shows strong expression of <italic>Adamts6</italic> and <italic>Adamts10</italic> in E13.5 perichondrium (arrow) and weaker expression in growth plate chondrocytes (arrowheads). (<bold>B</bold>) Strong <italic>Adamts6</italic> and <italic>Adamts10</italic> expression was seen in E14.5 tibia perichondrium, whereas only the peripheral chondrocytes expressed both genes. (<bold>C,D</bold>) At E14.5 <italic>Adamts6</italic> and <italic>Adamts10</italic> expression was seen, in addition to perichondrium, in knee joint mesenchyme (<bold>C</bold>), arrow; F, femur, T, tibia, while <italic>Adamts6</italic> was strongly expressed in the patellar tendon (<bold>C</bold>), arrowhead, PT. Both genes were expressed in the perichondrium, muscles and tendons around the hip, elbow tendons (arrow; H, humerus, R, radius) and muscle (arrowhead), and in the shoulder rotator cuff tendons (arrowhead, RC). (<bold>D</bold>) <italic>Adamts6</italic> and <italic>Adamts10</italic> were expressed in the vertebral endplates (arrows), rib intercostal muscles (arrows), Achilles tendon in the ankle (arrow; C, calcaneus), in perichondrium and tendons in the autopod.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig2-v1.tif"/></fig></sec><sec id="s2-4"><title><italic>Adamts6</italic>-deficient skeletal elements have abnormal growth plates with dramatically reduced cartilage proteoglycan</title><p>RGB trichrome-stained E18.5 sections revealed abnormal growth plate cartilage ECM, showing a dramatic reduction in staining with the alcian blue component, which detects sulfated proteoglycans, in <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> embryos (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The perichondrium and adjacent mesenchyme showed increased and diffuse staining of collagen in the <italic>Adamts6</italic>-deficient and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> femur (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). The reduction of alcian blue staining and diffuse collagen staining was evident in E14.5 <italic>Adamts6</italic><sup>-/-</sup> long bone, such as the femur (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> resting zone (RZ) chondrocytes were tightly packed compared to wild type with disorganized columnar zones (CZ) and hypertrophic zones (HZ), whereas <italic>Adamts10</italic><sup>-/-</sup> growth plates resembled the wild type (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To determine the basis for reduced alcian blue staining intensity, we immunostained for aggrecan, which revealed less intense staining in <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> cartilage as compared to control and <italic>Adamts10</italic><sup>-/-</sup> limbs and in E14.5 <italic>Adamts6</italic><sup>-/-</sup> femur (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B, C</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). Consistent with reduced aggrecan, we observed reduced staining of cartilage link protein, which stabilizes the aggregates formed by aggrecan and hyaluronan and for the key chondrogenic factor Sox9 in both E14.5 and E18.5 femoral growth plates (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B, C</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). In contrast, the HZ marker Col X revealed comparable staining in all genotypes, and suggested increased HZ thickness in <italic>Adamts10</italic><sup>-/-</sup>, <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> femur as compared to wild type, potentially related to delayed ossification (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). PCNA and TUNEL staining revealed no change in cell proliferation or cell death, respectively, in <italic>Adamts6</italic><sup>-/-</sup> femoral cartilage (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). These findings therefore indicate a substantial disruption of the <italic>Adamts6</italic>-mutant chondrocyte phenotype, which was exacerbated in the <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> mutants.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> hindlimbs have disorganized chondrocytes and reduced cartilage proteoglycan.</title><p>(<bold>A</bold>) RGB trichrome-stained E18.5 knees show disorganized chondrocytes and reduced alcian blue staining in <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> bones. (F), femur; T, tibia; f, fibula; RZ, resting zone; CZ, columnar zone; HZ, hypertrophic zone. (<bold>B</bold>) Severely reduced aggrecan (Acan), cartilage link protein (CLP) and Sox9 in <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> cartilage and wider collagen X (Col X)-stained region indicating an expanded HZ.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Increased collagen staining in <italic>Adamts6</italic>-deficent hindlimbs.</title><p>RGB trichrome-stained E18.5 femur showed diffuse, disorganized and increased collagen staining (red) in the perichondrium and adjacent mesenchyme in <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> embryos. These images are taken from panels in <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title><italic>Adamts6</italic>-deficent femora have reduced cartilage proteoglycan staining.</title><p>(<bold>A</bold>) RGB trichrome-stained E14.5 <italic>Adamts6</italic><sup>-/-</sup> femur sections show smaller resting zone (RZ), columnar zone (CZ) and hypertrophic zone (HZ) chondrocytes with reduced alcian blue staining of the ECM. (<bold>B, C</bold>) Reduced staining intensity of aggrecan (Acan), cartilage link protein (CLP) and Sox9 was seen in <italic>Adamts6</italic><sup>-/-</sup> proximal femoral distal resting chondrocytes. n ≥ 6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Late embryonic <italic>Adamts6</italic>-mutant femora have reduced cartilage proteoglycan.</title><p>Reduced staining intensity of aggrecan (Acan), cartilage link protein (CLP) and Sox9 were evident in <italic>Adamts6</italic><sup>-/-</sup> proximal femoral resting and columnar zone chondrocytes. No change in Col X staining intensity was noted. n ≥ 4. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>No change in proliferation or cell death in <italic>Adamts6</italic><sup>-/-</sup> cartilage.</title><p>(<bold>A–B</bold>) PCNA +nuclei (red) (<bold>A</bold>) in E18.5 distal femur were quantified in the resting zone (RZ; yellow brackets) and columnar zone (CZ; orange brackets) and quantified in (<bold>B</bold>). n = 4. (<bold>C–D</bold>) TUNEL +cells (green) (<bold>C</bold>) in E18.5 proximal femur were quantified (<bold>D</bold>) at the chondro-osseous junction (terminal hypertrophic chondrocytes).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig3-figsupp4-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Fibrillin<italic>-2</italic> and MAGP1 accumulate in <italic>Adamts6</italic><sup>-/-</sup><italic>, Adamts10</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> hindlimbs</title><p>Since prior work had shown that ADAMTS10 had a strong functional relationship with fibrillin microfibrils, specifically accelerating fibrillin-1 assembly and undertaking fibrillin-2 proteolysis (by the action of the small fraction of ADAMTS10 that is furin-processed) (<xref ref-type="bibr" rid="bib43">Kutz et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Mularczyk et al., 2018</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2019a</xref>), we investigated changes in fibrillin-1/–2 distribution and staining intensity in the mutant limbs using immunofluorescence. First, we stained for microfibril-associated glycoprotein 1 (MAGP1), which binds to both fibrillin-1 and fibrillin-2 (<xref ref-type="bibr" rid="bib36">Jensen et al., 2001</xref>), to report their combined abundance and detected increased staining intensity in <italic>Adamts10</italic><sup>-/-</sup>, <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> femur perichondrium (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Immunostaining with a monospecific fibrillin-2 antibody showed more intense perichondrial staining in <italic>Adamts10</italic><sup>-/-</sup>, <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> perichondrium (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) but comparable fibrillin-1 staining was observed (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). <italic>Fbn2</italic> and <italic>Fbn1</italic> mRNA levels were unchanged in <italic>Adamts6</italic>- and <italic>Adamts10</italic>-deficient hindlimbs, suggesting that increased fibrillin-2 staining was not a result of increased transcription (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Increased MAGP1 and fibrillin-2 staining, but not fibrillin-1 staining in <italic>Adamts6</italic><sup>-/-</sup> and <italic>Adamts6<sup>-/-</sup>;Adamts10<sup>-/-</sup></italic> perichondrium.</title><p>(<bold>A–B</bold>) Increased staining intensity (green) of MAGP1 (<bold>A</bold>) and fibrillin-2 (<bold>B</bold>) in E18.5 <italic>Adamts6</italic>- and <italic>Adamts10</italic>-deficient knee joints. (<bold>C</bold>) No consistent change in fibrillin-1 staining (green) was seen between the various genotypes. n = 3. Sections are counterstained with DAPI (blue). The inset boxes are enlarged in corresponding lower sections. White arrows indicate the perichondrium. F, femur; T, tibia; f, fibula.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Differential microfibril staining in <italic>Adamts6</italic>-deficient hindlimbs.</title><p>(<bold>A</bold>) Increased MAGP1 and fibrillin-2 staining intensity in <italic>Adamts6</italic>- and <italic>Adamts10</italic>-mutant hindlimbs. There was no change, however, in fibrillin-1 staining intensity. n ≥ 4. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. (<bold>B</bold>) Comparable <italic>Fbn2</italic> and <italic>Fbn1</italic> hindlimb RNA levels in <italic>Adamts6</italic> and <italic>Adamts10</italic> mutants as demonstrated by qRT-PCR analysis of E18.5 hindlimbs. n = 3.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>ADAMTS6 binds to fibrillin-2 microfibrils formed by cultured fibroblasts</title><p>To determine the functional relationship of ADAMTS6 to the two fibrillins, we investigated ADAMTS6 binding to homotypic fibrillin-2 or fibrillin-1 microfibrils assembled by <italic>Fbn1</italic><sup>-/-</sup> and <italic>Fbn2</italic><sup>-/-</sup> mouse embryo fibroblasts (MEFs), respectively. This specific approach allowed categoric examination of binding to each individual fibrillin, since when co-expressed, the fibrillins form heterotypic fibrils and thus isoform-specific binding cannot be otherwise discerned. Co-cultures of <italic>Fbn1</italic><sup>-/-</sup> MEFs with HEK293T cells stably expressing catalytically inactive ADAMTS6 (ADAMTS6 Glu<sup>404</sup>Ala, referred to hereafter as ADAMTS6 EA) for 6 days illustrated specific co-localization of ADAMTS6 EA with fibrillin-2 microfibrils (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, top row). When <italic>Fbn1</italic><sup>-/-</sup> MEFs were co-cultured with HEK293F cells expressing active ADAMTS6 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, 2nd row), no fibrillin-2 staining was seen, suggestive of proteolytic degradation of fibrillin-2 microfibrils or interference with their assembly. Similarly, 4-day-old cultures of <italic>Fbn2</italic><sup>-/-</sup> mouse skin fibroblasts (MSF) revealed co-localization of ADAMTS6 EA with fibrillin-1 and demonstrated absence of fibrillin-1 microfibrils in the presence of ADAMTS6 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, center panels). Since a fibronectin fibrillar matrix is formed soon after plating of cells and acts as a template for fibrillin microfibril assembly (<xref ref-type="bibr" rid="bib4">Beene et al., 2013</xref>; <xref ref-type="bibr" rid="bib72">Sabatier et al., 2009</xref>), we similarly analyzed fibronectin staining, observing that ADAMTS6 EA co-localized with fibronectin and that fibronectin fibrils were absent in the presence of ADAMTS6, suggesting also that over-expressed ADAMTS6 may cleave fibronectin (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, bottom panels). In agreement, MEFs isolated from <italic>Adamts6</italic><sup>-/-</sup> embryos showed greater fibrillin-2, fibrillin-1, and fibronectin microfibril staining intensity than wild type MEFs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Together, these findings suggested that ADAMTS6 binds to and proteolytically degrades fibronectin and fibrillin microfibrils or alternatively, unassembled fibrillin monomers prior to their assembly.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Loss of fibrillin-2, fibrillin-1 and fibronectin microfibrils in the presence of active ADAMTS6.</title><p>(<bold>A</bold>) <italic>Fbn1</italic><sup>-/-</sup> mouse embryo fibroblasts (MEFs), which can produce fibrillin-2 but not fibrillin-1, were cocultured with human embryonic kidney (HEK) cells overexpressing ADAMTS6 or ADAMTS6 EA (inactive ADAMTS6). Fibrillin-2 (green) co-localized with histidine (His)-tagged ADAMTS6 EA (red), but no microfibrils were seen in the presence of ADAMTS6 (red). Similarly, <italic>Fbn2</italic><sup>-/-</sup> mouse skin fibroblasts (MSFs), which can produce fibrillin-1 but not fibrillin-2, were co-cultured with HEK cells overexpressing ADAMTS6 or ADAMTS6 EA. Fibrillin-1 microfibrils (green) co-localized with His-tagged ADAMTS6 EA (red), but were absent in the presence of active ADAMTS6 (red) after 4 days culture. Fibronectin also co-localized with ADAMTS6 EA, and fibronectin fibrils were absent in the presence of ADAMTS6. Nuclei are stained with DAPI (blue). (<bold>B</bold>) Quantification of mean intensity of fluorescence. n ≥ 6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Increased fibrillin-1, fibrillin-2 and fibronectin microfibril staining in fibroblasts lacking ADAMTS6.</title><p>(<bold>A</bold>) <italic>Adamts6</italic><sup>-/-</sup> mouse embryo fibroblasts (MEFs) have increased fibrillin-2 and fibrillin-1 staining after 6 days in culture as compared to wild type MEFs. Fibronectin staining was similarly increased in 2 day cultures. Nuclei are stained with DAPI (blue). (<bold>B</bold>) Quantification of mean intensity of fluorescence. n ≥ 3. **p ≤ 0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Since fibrillin microfibrils contain additional components beside fibrillins (<xref ref-type="bibr" rid="bib7">Cain et al., 2006</xref>; <xref ref-type="bibr" rid="bib16">De Maria et al., 2017</xref>; <xref ref-type="bibr" rid="bib23">Fujikawa et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">Mecham and Gibson, 2015</xref>), which could bind to ADAMTS6, we next asked whether purified ADAMTS6 constructs bound directly to purified fibrillin-2 and fibrillin-1 in a sensitive binary interaction assay. Since ADAMTS proteases typically bind to their substrates via interactions of their C-terminal ancillary domains, and because of the difficulty in purifying full-length ADAMTS6, we used C-terminal ADAMTS6 constructs for these studies. Biacore analysis showed that C-terminal ADAMTS6 constructs (ADAMTS6-Ct, ADAMTS6-S4TSR and ADAMTS6-4TSR) bound the C-terminal half of fibrillin-2 (fibrillin-2-Ct) (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Since all 4TSR-array-containing constructs bound to fibrillin-2-Ct we concluded that the fibrillin-2 binding region of ADAMTS6 was located in the C-terminal TSR array. In reciprocal Biacore analysis using ADAMTS6-Ct as the immobilized ligand, its binding to both the N- and C-terminal halves of fibrillin-2 was observed (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, <xref ref-type="table" rid="table2">Table 2</xref>). Comparable K<sub>D</sub> values of 43 nM for fibrillin-2-Nt and 80 nM for fibrillin-2-Ct suggested two or more binding sites in each half of fibrillin-2 with similar affinities for ADAMTS6. Alternatively, the ADAMTS6 binding site on fibrillin-2 may lie in the overlapping region of the two fragments between cbEGF22 and cbEGF24. Consistent with prior work showing ADAMTS6 binding to fibrillin-1 (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>), ADAMTS6-Ct bound to fibrillin-1 N- and C-terminal halves (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A, B</xref>), although stronger binding was observed to the N-terminal half (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). In summary, these high-affinity binary interactions suggested that ADAMTS6 binds directly to both fibrillin-1 and fibrillin-2 to cleave them.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>ADAMTS6 binds directly to fibrillin-2.</title><p>(<bold>A</bold>) Cartoons of the domain structures of ADAMTS6 and fibrillin-2 and the recombinant constructs used in the present work (indicated by black lines). (<bold>B–C</bold>) Biacore analysis shows dose-dependent binding curves for the ADAMTS6-C-terminal constructs ADAMTS6-Ct, ADAMTS6-4TSR and ADAMTS6-S4TSR against immobilized FBN2-Ct (<bold>B</bold>), and comparative binding characteristics of the constructs (<bold>C</bold>), other than ADAMTS6-TCS, which did not bind. (<bold>D</bold>) Reciprocal Biacore analysis using immobilized ADAMTS6-Ct shows that fibrillin-2-Nt and fibrillin-2-Ct used as the analyte each bound strongly to ADAMTS6-Ct.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>ADAMTS6 binds directly to fibrillin-1.</title><p>(<bold>A</bold>) Domain structure of fibrillin-1 recombinant constructs. (<bold>B</bold>) Biacore analysis shows that fibrillin-1-Nt and fibrillin-1-Ct recombinant fragments each bind strongly to ADAMTS6-Ct. (<bold>C</bold>). Comparison of fibrillin-1 and fibrillin-2 binding shows strongest binding of ADAMTS6-Ct to FBN1-Nt among the tested fibrillin constructs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig6-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Kinetic data for ADAMTS6 construct binding to FBN2-Ct.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3" valign="bottom">Ligand: FBN2-Ct</th><th align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom">Analyte</th><th align="center" valign="bottom">K<sub>D</sub> (nM)</th><th align="center" valign="bottom">R<sup>2</sup></th><th align="center" valign="bottom">B<sub>max</sub> (RU)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>ADAMTS6-Ct</bold></td><td align="center" valign="bottom">436</td><td align="center" valign="bottom">0.9951</td><td align="center" valign="bottom">727</td></tr><tr><td align="left" valign="bottom"><bold>ADAMTS6-4TSR</bold></td><td align="center" valign="bottom">122</td><td align="center" valign="bottom">0.8864</td><td align="center" valign="bottom">188</td></tr><tr><td align="left" valign="bottom"><bold>ADAMTS6-S4TSR</bold></td><td align="center" valign="bottom">114</td><td align="center" valign="bottom">0.9819</td><td align="center" valign="bottom">241</td></tr></tbody></table></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Kinetic data for binding of FBN2 constructs to ADAMTS6-Ct.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3" valign="bottom">Ligand: ADAMTS6-Ct</th><th align="left" valign="bottom"/></tr><tr><th align="left" valign="bottom">Analyte</th><th align="center" valign="bottom">K<sub>D</sub> (nM)</th><th align="center" valign="bottom">R<sup>2</sup></th><th align="center" valign="bottom">B<sub>max</sub> (RU)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>FBN2-Nt</bold></td><td align="center" valign="bottom">43</td><td align="center" valign="bottom">0.9972</td><td align="center" valign="bottom">85</td></tr><tr><td align="left" valign="bottom"><bold>FBN2-Ct</bold></td><td align="center" valign="bottom">80</td><td align="center" valign="bottom">0.9933</td><td align="center" valign="bottom">100</td></tr></tbody></table></table-wrap></sec><sec id="s2-7"><title>N-terminomics identification and orthogonal validation of an ADAMTS6 cleavage site in fibrillin-2</title><p>Direct binding of ADAMTS6 constructs to recombinant fibrillin-2, ADAMTS6 EA co-localization with fibrillin-2 microfibrils, loss of fibrillin-2 microfibrils in vitro in the presence of wild-type ADAMTS6, and increased fibrillin-2 staining in <italic>Adamts6</italic>-deficient hindlimbs suggested that fibrillin-2 was likely to be an ADAMTS6 substrate. To define the cleavage site(s), HEK293F cells stably expressing the N- or C-terminal halves of fibrillin-2 were transfected with either ADAMTS6 or ADAMTS6 EA and the serum-free conditioned medium was collected for Terminal Amine Isotopic Labeling of Substrates (TAILS) (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), an N-terminomics strategy for identifying protease substrates and cleavage sites (<xref ref-type="bibr" rid="bib40">Kleifeld et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Grant and Li, 2016</xref>). This strategy was previously applied for identification of substrates of other ADAMTS proteases (<xref ref-type="bibr" rid="bib5">Bekhouche et al., 2016</xref>). Proteins were labeled with stable isotopes of formaldehyde (natural (CH<sub>2</sub>O)/light isotope applied to the ADAMTS6-containing medium or isotopically heavy (<sup>13</sup>CD<sub>2</sub>O), applied to the ADAMTS6 EA-containing medium). The ensuing reductive dimethylation labels and blocks free protein N-termini as well as lysine side-chains. Labeled proteins from each pair of ADAMTS6/ADAMTS6 EA digests were combined, digested with trypsin to obtain peptides and mixed with hyperbranched polyglycerol aldehyde polymer which binds to free N-termini of tryptic peptides to exclude them (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), enriching the peptides having blocked and labeled N-termini for liquid chromatography tandem mass spectrometry (LC-MS/MS). Following LC-MS/MS, we undertook a targeted search for fibrillin-2 peptides with isotopically labeled N-termini having a statistically significant light:heavy ratio. This analysis revealed a putative cleavage site at the Gly<sup>2158</sup>-His<sup>2159</sup> peptide bond in a linker between TGFβ binding-like domain 6 and calcium-binding epidermal growth factor (cbEGF) repeat 32 in the C-terminal half of fibrillin-2 (<xref ref-type="fig" rid="fig7">Figure 7B–F</xref>). The sequence of the indicator peptide, which was semi-tryptic, and therefore unlikely to result from trypsin digestion during sample preparation and the presence of an N-terminal label was determined with high confidence by the MS<sup>2</sup> spectrum (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Quantification of the relative ion abundance of isotoptically labeled peptides showed a considerable excess of this peptide in the presence of active ADAMTS6 (<xref ref-type="fig" rid="fig7">Figure 7D–E</xref>). Western blot of the medium from these experiments for orthogonal validation of the cleavage showed that ADAMTS6 cleaved the C-terminal half of fibrillin-2 (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). The cleavage products of 100 kDa and 75 kDa matched the predicted cleavage fragments in size and their sum matched the expected mass of the FBN2-Ct construct (175 kDa). Importantly, the Gly<sup>2158</sup>-His<sup>2159</sup> cleavage site is located between two folded, disulfide-bonded domains, predicting separation of the resulting fragments (as opposed to cleavage sites within disulfide-bonded fibrillin-2 domains that would remain linked). The cleavage can potentially interfere with microfibril assembly, which is reliant on multimerization via C-terminal interactions downstream of the cleavage site (<xref ref-type="bibr" rid="bib30">Hubmacher et al., 2008</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Fibrillin-2 cleavage by ADAMTS6 and identification of the cleavage site using N-terminomics.</title><p>(<bold>A</bold>) Schematic of the experimental approach. Proteins from conditioned medium of co-cultures of HEK293F cells stably expressing FBN2-Ct and HEK293F cells expressing either ADAMTS6 WT or ADAMTS6 EA (inactive control) were labeled by reductive dimethylation using stable formaldehyde isotopes and analyzed by LC-MS/MS in the TAILS workflow described in detail in the Methods section. (<bold>B</bold>) MS1 chromatogram of the parent ions derived from fibrillin-2 fragments potentially resulting from cleavage by ADAMTS6 (black) and the same peptides sought in ADAMTS6 EA-containing medium (red) that were used for measuring abundance. (<bold>C</bold>) Annotated MS<sup>2</sup> spectrum of the light (ADAMTS6-generated) dimethyl peptide, showing b-(N-terminus preserved) and y-type (C-terminus preserved) ions generated by amide bond cleavage during collisional-induced dissociation that were used to derive the fibrillin-2 peptide sequence indicated at the top right. (<bold>D</bold>) Retention time-aligned extracted ion chromatograms (EICs) comparing abundance of the light dimethyl-labeled HGTVPSLHDTR peptide (blue) in ADAMTS6 medium and isotopically heavy dimethyl-labeled peptide (orange) in ADAMTS6 EA medium from three replicate TAILS experiments. (<bold>E</bold>) The area under the EIC curves was quantified and comparison of ion abundance is shown in a dumb-bell plot (from 3 TAILS and 3 pre-TAILS samples). Significance was determined using a two-tailed, paired Student t-test, * indicates p-value &lt; .05. (<bold>F</bold>) Domain structure of fibrillin-2 and the C-terminal construct FBN2-Ct showing the location of the cleaved peptide bond Gly<sup>2158</sup>-His<sup>2159</sup> in the linker between TB6 and cbEGF32. (<bold>G</bold>) Orthogonal validation of fibrillin-2 cleavage by ADAMTS6 using western blot analysis of the conditioned medium from A, shows distinct molecular species (100 kDa and 75 kDa) reactive with anti-fibrillin-2-Ct antibody (green, N-terminal fragment of fibrillin-2-Ct) and C-terminal anti-His<sub>6</sub> antibody (red, C-terminal fragment of fibrillin-2-Ct), respectively, obtained in the presence of ADAMTS6 WT, but not ADAMTS6 EA, indicative of fibrillin-2-Ct cleavage. The green band of ~350 kDa is endogenous fibrillin-2 produced by HEK293F cells. The yellow band at ~175 kDa indicates overlapping anti-His<sub>6</sub> and anti-fibrillin-2-Ct antibody staining of the fibrillin-2-Ct construct. Cells transfected with empty vector were also used to obtain control medium.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>ADAMTS6 cleaves fibrillin-1.</title><p>(<bold>A</bold>) Schematic of the experimental approach. Proteins from conditioned medium of co-cultured HEK293F cells stably expressing fibrillin-1 and HEK293F cells expressing either ADAMTS6 WT or ADAMTS6 EA (inactive) were labeled by reductive dimethylation using stable formaldehyde isotopes and analyzed by LC-MS/MS in the TAILS workflow described in detail in the Materials and methods section. (<bold>B</bold>) Domain structure of fibrillin-1 showing the location of the cleaved peptide bond Arg<sup>516</sup>-Ala<sup>517</sup> between EGF4 and cbEGF3. (<bold>C</bold>) Annotated MS<sup>2</sup> spectrum of the fibrillin-1 peptide shows the b- (N-terminal preserved) and y-type (C-terminal preserved) ions generated via amide bond cleavage during collision-induced dissociation revealing the peptide backbone sequence. (<bold>D</bold>) The retention time-aligned extracted ion chromatograms show the light dimethyl-labeled AGYQSLTR peptide (blue) from the ADAMTS6 medium compared to the isotopically heavy dimethyl labeled peptide (orange) from the ADAMTS6 EA medium. (<bold>E</bold>) The area under the extracted chromatogram curve was quantified in three replicates TAILS experiments and plotted. Significance was determined using a two-tailed, paired Student t-test, *p ≤ 0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>ADAMTS6 cleaves fibronectin at multiple sites.</title><p>(<bold>A</bold>) Schematic of the domain structure of fibronectin and locations of the identified cleavage sites. (<bold>B–C</bold>) Annotated MS<sup>2</sup> spectra of the VREEVVTVGNSVNEG (<bold>B</bold>) and the LNQPTDDSCFDPYTVSHYAVGDEWER (<bold>C</bold>) peptides are shown as examples. (<bold>D–E</bold>) Extracted ion chromatograms showing the peptide intensity and retention time in the ADAMTS6 medium but no matching chromatographic trace in the ADAMTS6 EA medium for peptides VREEVVTVGNSVNEG (<bold>D</bold>) and LNQPTDDSCFDPYTVSHYAVGDEWER (<bold>E</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig7-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-8"><title>ADAMTS6 cleaves fibrillin-1 and fibronectin</title><p>Because ADAMTS6 also bound directly to fibrillin-1, TAILS was applied in a similar approach as above to determine if ADAMTS6 cleaved fibrillin-1 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). A targeted search for fibrillin-1 peptides with labeled N-termini revealed a putative cleavage site at the R<sup>516</sup>-A<sup>517</sup> peptide bond in a linker between EGF4 and cbEGF3 in the N-terminal half (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). The peptide sequence and presence of an N-terminal label was determined with high confidence by the MS<sup>2</sup> spectrum and quantification of the ion abundance showed a considerable excess of this peptide in the presence of ADAMTS6 (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C-E</xref>).</p><p>To determine whether ADAMTS6 cleaved fibronectin, ADAMTS6 or ADAMTS6 EA-expressing stable cell lines were plated on human fibronectin-coated plates and the serum-free medium from these cultures was collected 24 hr later. By comparing the ratio of light:heavy dimethyl-labeled peptides, TAILS revealed several potential cleavage sites in the medium from the ADAMTS6 sample (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>) (<xref ref-type="table" rid="table3">Table 3</xref>). As an example, annotated spectra of two of the peptides and their extracted ion chromatograms illustrate the lack of the corresponding peaks in medium of the ADAMTS6 EA samples, indicating fibronectin cleavage solely in the presence of catalytically active ADAMTS6 (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2B-E</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Putative sites of fibronectin cleavage by ADAMTS6 determined using TAILS.</title><p>The cleavage site is indicated by the period in column 1, with flanking amino acids numbered.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Annotated sequence</th><th align="center" valign="bottom">Number of PSMs</th><th align="center" valign="bottom">Wild type abundance</th><th align="center" valign="bottom">EA abundance</th></tr></thead><tbody><tr><td align="left" valign="bottom">[A<sup>292</sup>].V<sup>293</sup>YQPQPHPQPPPYGHCVTDSGVVYSVGMQWLK.[T]</td><td align="center" valign="bottom">2</td><td align="center" valign="bottom">1.38E + 06</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[Y<sup>294</sup>].Q<sup>295</sup>PQPHPQPPPYGHCVTDSGVVYSVGMQWLK.[T]</td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">6.99E + 05</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[P<sup>462</sup>].M<sup>463</sup>AAHEEICTTNEGVMYR.[I]</td><td align="center" valign="bottom">2</td><td align="center" valign="bottom">1.22E + 06</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[A<sup>464</sup>].A<sup>465</sup>HEEICTTNEGVMYR.[I]</td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">4.71E + 05</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[G<sup>567</sup>].T<sup>568</sup>FYQIGDSWEK.[Y]</td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">1.18E + 06</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[F<sup>750</sup>].R<sup>751</sup>VEYELSEEGDEPQYLDLPSTATSVNIPDLLPGRK.[Y]</td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">3.33E + 05</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[K].YIVNVYQISEDGEQS<sup>800</sup>.[L<sup>801</sup>]</td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">8.57E + 05</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[Y<sup>1248</sup>].T<sup>1249</sup>VKDDKESVPISDTIIPAVPPPTDLR.[F]</td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">1.21E + 06</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[Y<sup>1613</sup>].A<sup>1614</sup>QNPSGESQPLVQTAVTTIPAPTDLK.[F]<sup><xref ref-type="table-fn" rid="table3fn3">†</xref></sup></td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">6.32E + 05</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[P<sup>2021</sup>].F<sup>2022</sup>VTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRR.[T]</td><td align="center" valign="bottom">2</td><td align="center" valign="bottom">1.58E + 06</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[K].VREEVVTVGNSVNEG<sup>2197</sup>.[L<sup>2198</sup>]<sup><xref ref-type="table-fn" rid="table3fn2">*</xref></sup></td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">1.56E + 06</td><td align="center" valign="bottom">0</td></tr><tr><td align="left" valign="bottom">[G<sup>2197</sup>].L<sup>2198</sup>NQPTDDSCFDPYTVSHYAVGDEWER.[M]<sup><xref ref-type="table-fn" rid="table3fn2">*</xref></sup></td><td align="center" valign="bottom">1</td><td align="center" valign="bottom">6.82E + 06</td><td align="center" valign="bottom">0</td></tr></tbody></table><table-wrap-foot><fn><p><underline>Abbreviations used</underline>: PSM, Peptide spectrum matches.</p></fn><fn id="table3fn2"><label>*</label><p>Peptides with termini identifying the same cleavage site (G<sup>2197</sup>-L<sup>2198</sup>).</p></fn><fn id="table3fn3"><label>†</label><p>Peptide unique to the FN1-8 isoform.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-9"><title>Fibrillin-2 reduction, but not fibrillin-1 reduction specifically reverses morphogenetic and molecular defects in <italic>Adamts6<sup>-/-</sup></italic> mice</title><p>Identification of fibrillin-1, fibrillin-2 and fibronectin as ADAMTS6 substrates, yet observation of only fibrillin-2 accumulation in the hindlimbs suggested that while all three ECM components could be cleaved by ADAMTS6, fibrillin-2 could either be a preferred substrate, or not as extensively cleaved by other proteases active during limb development, which may compensate for the absence of ADAMTS6. We therefore undertook a genetic approach to determine the importance of fibrillin-2 and fibrillin-1 with regards to ADAMTS6 activity. To test whether fibrillin-2 had a significant role in the observed anomalies, fibrillin-2 was reduced genetically in <italic>Adamts6</italic><sup>-/-</sup> mice. <italic>Fbn2</italic> haploinsufficiency dramatically restored the external craniofacial and hindlimb morphology of <italic>Adamts6</italic> mutants as well as the maturity, length and shape of skeletal components of the hindlimb and axial skeleton (<xref ref-type="fig" rid="fig8">Figure 8A and B</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A, B</xref>, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2A</xref>). Specifically, alizarin red and alcian blue-stained skeletal preparations demonstrated reversal of reduced crown-rump length, long bone shortening and improved ossification of hindlimb long bones and ribs, an appropriately segmented sternum with a normal xiphoid process and normal fontanelle closure (<xref ref-type="fig" rid="fig8">Figure 8A and B</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2A</xref>). In addition, cleft secondary palate which occurred with a high incidence in <italic>Adamts6</italic><sup>-/-</sup> embryos, was not observed in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn</italic>2<sup>+/-</sup> embryos (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2B</xref>). <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn</italic>2<sup>+/-</sup> hindlimb fibrillin-2 staining showed reduced intensity comparable to wild type hindlimb (<xref ref-type="fig" rid="fig8">Figure 8C</xref>, <xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3</xref>). Aggrecan, cartilage link protein and Sox9 staining intensity in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn</italic>2<sup>+/-</sup> femur growth plates were restored to comparable levels as in wild type limbs, indicating restoration of the appropriate ECM of cartilage (<xref ref-type="fig" rid="fig8">Figure 8D</xref>, <xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3</xref>). <italic>Fbn2</italic><sup>+/-</sup> embryos had normal hindlimb development and growth plate zone organization as wild type controls (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3</xref>, <xref ref-type="fig" rid="fig8s4">Figure 8—figure supplement 4C-E</xref>). In contrast to <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn</italic>2<sup>+/-</sup> embryos, <italic>Adamts6</italic><sup>-/-</sup> embryos with ~80% reduction in fibrillin-1 levels (<italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn1</italic><sup>mgR/mgR</sup> embryos) had no amelioration of limb defects (<xref ref-type="fig" rid="fig8s5">Figure 8—figure supplement 5A, B</xref>). Taken together, these genetic analyses using well-characterized <italic>Fbn1</italic> and <italic>Fbn2</italic> mutants<italic>,</italic> suggested a specific role for ADAMTS6 in modulating fibrillin-2 abundance during limb microfibril proteostasis.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Genetic reversal of limb anomalies in <italic>Adamts6</italic> mutant mice by <italic>Fbn2</italic> haploinsufficiency.</title><p>(<bold>A–B</bold>) Deletion of one <italic>Fbn2</italic> allele reverses limb dysmorphology in E18.5 <italic>Adamts6</italic><sup>-/-</sup> embryos, specifically, externally evident limb segment dimensions and reversal of rotational anomaly (arrow) (<bold>A</bold>), normal ossific centers and overall hindlimb skeletal structure, reversal of internal rotation and bending of the tibia (arrowheads) and restores normal tibial and fibular (arrows) length, shape and alignment (<bold>B</bold>). The lower panels in (<bold>B</bold>) illustrate the tibia and fibula (arrowhead) at higher magnification. (<bold>C</bold>) Fibrillin-2 staining is reduced to wild type levels in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> distal femoral perichondrium. T, tibia, F, femur. (<bold>D</bold>) Restitution of aggrecan, cartilage link protein (CLP) and Sox9 staining in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> distal femoral cartilage. T, tibia, F, femur.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Reversal of reduced body length and long bone shortening in <italic>Adamts6</italic>-deficient embryos by <italic>Fbn2</italic> hemizygosity.</title><p>Reduced crown-rump length (<bold>A</bold>) and reduced radius, ulna, tibia and fibula length (<bold>B</bold>) in E18.5 <italic>Adamts6<sup>-</sup></italic><sup>/-</sup> embryos was ameliorated by <italic>Fbn2</italic> heterozygosity. Crown-rump length, n ≥ 3; bone length, n ≥ 6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig8-figsupp1-v1.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title><italic>Fbn2</italic> haploinsufficiency reverses axial skeleton and craniofacial anomalies in <italic>Adamts6<sup>-</sup></italic><sup>/-</sup> mice.</title><p>The images specifically illustrate restoration of length, ossification and relative proportions of the ribs (astrisks), sternal segmental ossific centers (arrows) and xiphoid process ossification (arrowheads), vertebral body (arrows) and vertebral appendage ossification, as well as skull dimensions and parietal ossification (dashed white line). (<bold>B</bold>) Hematoxylin and eosin-stained coronal sections from E18.5 embryos show that <italic>Fbn2</italic> haploinsufficiency reverses cleft secondary palate (asterisk) observed in the majority of <italic>Adamts6</italic><sup>-/-</sup> mutants (the observed incidence of cleft palate is listed below the respective panels).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig8-figsupp2-v1.tif"/></fig><fig id="fig8s3" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 3.</label><caption><title>Normalized fibrillin-2, aggrecan, cartilage link protein and Sox9 staining intensity in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> cartilage.</title><p>Reduction of fibrillin-2 staining intensity was noted in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> hindlimbs compared to <italic>Adamts6</italic><sup>-/-</sup> hindlimbs. <italic>Fbn2</italic><sup>+/-</sup> hindlimbs also had reducedfibrillin-2 staining than wild type hindlimb. The staining intensity of aggrecan (Acan) cartilage link protein (CLP) and Sox9 were restored in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> cartilage as compared to <italic>Adamts6</italic><sup>-/-</sup> cartilage. n ≥ 4. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig8-figsupp3-v1.tif"/></fig><fig id="fig8s4" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 4.</label><caption><title><italic>Fbn2</italic> hemizygosity does not itself alter hindlimb long bone length or growth plate morphology and dimensions.</title><p>(<bold>A,B</bold>) Alcian blue- and alizarin red-stained E18.5 <italic>Fbn2</italic><sup>+/-</sup> hindlimbs have normal patterning and unchanged long bone length (n ≥ 12). No change in crown-rump length was seen in E18.5 <italic>Fbn2</italic><sup>+/-</sup> embryos (n ≥ 6). (<bold>C,D</bold>) RGB trichrome-stained E18.5 <italic>Fbn2</italic><sup>+/-</sup> distal femur showed no change in chondrocyte appearance or growth plate zones when compared to control. F, femur; T, tibia; RZ, resting zone; CZ, columnar zone; HZ, hypertrophic zone (n ≥ 6). (<bold>E</bold>) Fibrillin-2 staining was reduced in <italic>Fbn2</italic><sup>+/-</sup> knee joints as compared to control (n ≥ 4). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig8-figsupp4-v1.tif"/></fig><fig id="fig8s5" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 5.</label><caption><title>Genetic <italic>Fbn1</italic> reduction does not affect <italic>Adamts6</italic><sup>-/-</sup> limb and skeletal defects.</title><p>No restoration of long bone dysmorphology and shortening (<bold>A,B</bold>) or crown-rump length (<bold>B</bold>) of <italic>Adamts6</italic><sup>-/-</sup> embryos after hemizygosity or homozygosity for a <italic>Fbn1</italic> mutant allele, <italic>Fbn1</italic><sup>mgR</sup>. Measurements were made in E18.5 embryos of the indicated genotypes. Crown-rump length, n ≥ 4; bone length, n ≥ 4. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig8-figsupp5-v1.tif"/></fig></fig-group></sec><sec id="s2-10"><title><italic>Adamts6</italic><sup>-/-</sup> hindlimbs and cartilage have abnormal GDF5 sequestration and reduced BMP signaling respectively</title><p>Since fibrillins are implicated in signaling of TGFβ and BMP/GDF signaling via sequestration and activation of these growth factors (<xref ref-type="bibr" rid="bib78">Sengle et al., 2015</xref>; <xref ref-type="bibr" rid="bib65">Nistala et al., 2010</xref>; <xref ref-type="bibr" rid="bib24">Furlan et al., 2021</xref>; <xref ref-type="bibr" rid="bib68">Ramirez and Rifkin, 2009</xref>; <xref ref-type="bibr" rid="bib87">Wohl et al., 2016</xref>), we investigated the impact of ADAMTS6 mutation on TGFβ and GDF/BMP signaling. <italic>Adamts6</italic><sup>-/-</sup> hindlimb long bones had reduced pSmad1/5/8 staining compared to wild type, which was restored to wild type levels in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn</italic>2<sup>+/-</sup> hindlimbs (<xref ref-type="fig" rid="fig9">Figure 9A, B</xref>). Similarily, pSMAD5 was reduced in <italic>Adamts6</italic><sup>-/-</sup> hindlimb extracts and restored to normal levels in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn</italic>2<sup>+/-</sup> hindlimb extracts (<xref ref-type="fig" rid="fig9">Figure 9C, D</xref>). In contrast, no change in TGFβ signaling, as measured by pSMAD2 immunostaining and western blot, occurred in <italic>Adamts6</italic><sup>-/-</sup> hindlimbs (<xref ref-type="fig" rid="fig9">Figure 9E–H</xref>).</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Reduced BMP signaling but unaltered canonical TGFβ signaling in <italic>Adamts6</italic><sup>-/-</sup> distal femur.</title><p>(<bold>A</bold>) Reduced pSMAD1/5/8 staining in <italic>Adamts6</italic><sup>-/-</sup> femur, as compared to wild type control, is restored to wild type levels in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> femur as quantified in (<bold>B</bold>). n ≥ 4; *p ≤ 0.05; **p ≤ 0.01. (<bold>C</bold>) Western blotting of E18.5 hindlimb extracts shows reduced pSMAD5 (green; 58 kDa). Anti-GAPDH (red, 37 kDa) was used as a loading control. (<bold>D</bold>) pSMAD5 levels from the western blot in (<bold>C</bold>) was quantified after normalization to GAPDH loading control. n = 3. *p ≤ 0.05. (<bold>E</bold>) No change in pSMAD2 staining in <italic>Adamts6</italic><sup>-/-</sup> femur as compared to wild-type control. The results are quantified in (<bold>F</bold>). (<bold>G</bold>) Western blot analysis shows no change in anti-pSMAD2 (green; 52 kDa) in <italic>Adamts6</italic>-deficient E18.5 hindlimb lysates. Anti-GAPDH (red, 37 kDa) was used as a loading control. (<bold>H</bold>) Quantification of anti-pSMAD2 signal in (<bold>G</bold>) using GAPDH signal intensity as the control. n = 3.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig9-v1.tif"/></fig><p>Several BMPs and GDFs bind fibrillin-2 directly through their propeptides (<xref ref-type="bibr" rid="bib24">Furlan et al., 2021</xref>; <xref ref-type="bibr" rid="bib87">Wohl et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Gregory et al., 2005</xref>; <xref ref-type="bibr" rid="bib76">Sengle et al., 2008</xref>; <xref ref-type="bibr" rid="bib77">Sengle et al., 2011</xref>). We therefore considered the possibility that increased fibrillin-2 in <italic>Adamts6</italic>-deficent hindlimbs resulted in sequestration of BMPs/GDFs. Antibodies applicable for immunostaining of mouse tissues are available for very few of these; accordingly, we co-immunostained sections with a fibrillin-2 antibody and a GDF5 antibody. We consistently observed stronger co-localized fibrillin-2 and GDF5 signal in <italic>Adamts6</italic> mutant knee joint mesenchyme, as well as in the perichondrium and interjoint regions in distal limbs, which are at less mature stages of development and have abundant undifferentiated limb mesenchyme (illustrated in knee joint interzone in <xref ref-type="fig" rid="fig10">Figure 10A–C</xref>, <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1A</xref>). Thus, increased fibrillin-2 was associated with increased GDF5 sequestration in <italic>Adamts6</italic>-deficent limbs.</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>GDF5 co-localizes with fibrillin-2 microfibrils with greater staining intensity in <italic>Adamts6</italic><sup>-/-</sup> knee joints.</title><p>(<bold>A–B</bold>) E14.5, E16.5 and E18.5 <italic>Adamts6</italic><sup>-/-</sup> knee joints (<bold>A</bold>) and perichondrium (<bold>B</bold>) show both increased fibrillin-2 (red) and GDF5 (green) staining in joint mesenchyme as compared to wild-type control. Note the overlapping staining of fibrillin-2 (red) and GDF5 (green) with increased immunodetection of both fibrillin-2 and GDF5 in the <italic>Adamts6</italic><sup>-/-</sup> knee joint mesenchyme. F, femur; T, tibia.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig10-v1.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>Increased fibrillin-2 and GDF5 staining intensity in <italic>Adamts6</italic><sup>-/-</sup> knee joint mesenchyme.</title><p>Quantification of fluorescent staining intensity in sections of the E14.5, E16.5, and E18.5 knee joint from wild type and <italic>Adamts6</italic><sup>-/-</sup> embyros stained with fibrillin-2 and GDF5 antibodies. n ≥ 4. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig10-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Regulated ECM proteostasis is required for ensuring proper adult tissue function (mitigating the risk of organ fibrosis, for example), but presumably also occurs during transition from the early to late embryo ECM, and may be a major determinant of adaptation of embryonic tissues to the dramatically different postnatal mechanical and regulatory landscapes. Because of the diversity of molecules and networks that comprise the ECM and existence of numerous secreted proteases, we hypothesized that selective proteolysis by specific proteases having preferred ECM substrates, may have a crucial role in ECM proteostasis in specific contexts of embryonic development. One example of a specific ECM proteostatic phenomenon mediated by ADAMTS proteases that influences embryonic cell behavior and is strongly supported by mouse genetic models is their role in versican turnover during interdigital web regression (<xref ref-type="bibr" rid="bib17">Dubail et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">McCulloch et al., 2009</xref>; <xref ref-type="bibr" rid="bib63">Nandadasa et al., 2021</xref>). Other than this example, little is known about the fate of macromolecular ECM complexes, especially those formed by homologous proteins with different stoichiometry in the embryo versus adult, and their proteostatic mechanisms.</p><p>Here, using a combination of genetic, biochemical, cell culture and proteomics approaches, we have identified ADAMTS6 and ADAMTS10 as major participants in fine-tuning of fibrillin microfibrils during limb development. Although prior work linked ADAMTS10 to genetic conditions that also resulted from <italic>FBN1</italic> mutations, the existence of a closely related homolog, ADAMTS6, raised questions about the role of transcriptional adaptation in this protease pair, their overlapping functions on an organ, tissue and molecular scale, the identity of their specific targets and relevant function in regard to fibrillin-1 and fibrillin-2. Resolution of these questions provides a conceptual precedent and strategic framework for elucidation of embryonic ECM proteostatic mechanisms, about which little is known relative to cellular homeostatic mechanisms in the embryo.</p><p>Prior work showed that transcriptional adaptation is operational in genes encoding paired homologous proteases ADAMTS7 and ADAMTS12, and is potentially a broad phenomenon in this family, whose mammalian members have arisen largely from gene duplication (<xref ref-type="bibr" rid="bib33">Huxley-Jones et al., 2005</xref>). Although the present study illustrates application of the phenomenon to the homologous pair of <italic>Adamts6</italic> and <italic>Adamts10</italic>, the two proteases are clearly distinct in their biological functions as outlined in prior and present work. While the combined knockouts clearly had a more severe phenotype (indicating cooperative function), it is presently not possible to demarcate the relative contributions of transcriptional buffering to mitigation of the individual phenotypes.</p><p>In the context of mechanisms that would ensure fibrillin-1 predominance postnatally, prior RNA in situ hybridization analysis had demonstrated dramatic reduction of <italic>Fbn2</italic> mRNA expression after birth, with <italic>Fbn1</italic> expression continuing (<xref ref-type="bibr" rid="bib90">Zhang et al., 1995</xref>) and corresponding to this, little fibrillin-2 is detected immunohistochemically or by proteomics in adult mouse tissues (<xref ref-type="bibr" rid="bib16">De Maria et al., 2017</xref>; <xref ref-type="bibr" rid="bib30">Hubmacher et al., 2008</xref>; <xref ref-type="bibr" rid="bib6">Cain et al., 2005</xref>; <xref ref-type="bibr" rid="bib15">Dallas et al., 2000</xref>; <xref ref-type="bibr" rid="bib38">Kettle et al., 1999</xref>; <xref ref-type="bibr" rid="bib39">Kinsey et al., 2008</xref>). Thus, differential transcription of fibrillin genes favors reduced fibrillin-2 synthesis postnatally, and together with dominance of <italic>Fbn1</italic> expression, was thought to underlie the prevalence of fibrillin-1 microfibrils in juvenile and adult mice. Fibrillin-2 was identified postnatally in only a few locations, and in some tissues, microfibril bundles had a core of fibrillin-2 microfibrils surrounded by abundant fibrillin-1, suggesting that postnatal microfibrils (comprising fibrillin-1) were added on pre-existing fibrillin-2-rich microfibrils (<xref ref-type="bibr" rid="bib16">De Maria et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Charbonneau et al., 2010</xref>). Previous work also suggested that fibrillin-2 epitope availability was masked postnatally by such overlay of fibrillin-1. Specifically, it was shown that fibrillin-2 staining in postnatal tissues such as perichondrium was enhanced by digestion with collagenase, that microfibrils treated with chaotropic agent had enhanced reactivity to fibrillin-2 antibodies, and that <italic>Fbn1</italic> null juvenile mice, which die by 2 weeks of age, had robust fibrillin-2 staining (<xref ref-type="bibr" rid="bib11">Charbonneau et al., 2010</xref>). Thus, it was thought that the fibrillin isoform content of microfibrils is substantially determined by the level of transcription of the respective genes and that fibrillin-2 fibrils are mostly masked postnatally, such that they may not have much of a regulatory role. The fate of fibrillin-2 microfibrils produced in the embryonic period, the possibility of specific proteolytic mechanisms to reduce their abundance, and a deleterious impact of fibrillin-2 overabundance on morphogenesis had not been previously considered and no animal models with excess fibrillin-2 are available.</p><p>The present work suggests that ADAMTS6 and ADAMTS10 work collaboratively, but in distinct ways, to support prevalence of fibrillin-1 in microfibrils after birth. ADAMTS10 is innately resistant to activation by furin, with only a small proportion converted to an active protease. ADAMTS10 promotes fibrillin-1 microfibril assembly (<xref ref-type="bibr" rid="bib43">Kutz et al., 2011</xref>), consistent with the observation that recessive <italic>ADAMTS10</italic> mutations and dominantly inherited <italic>FBN1</italic> mutations each lead to Weill-Marchesani syndrome (<xref ref-type="bibr" rid="bib14">Dagoneau et al., 2004</xref>; <xref ref-type="bibr" rid="bib21">Faivre et al., 2003a</xref>). ADAMTS10 was therefore thought to function akin to several ADAMTS-like proteins, which lack catalytic activity, and accelerate biogenesis of fibrillin-1 containing microfibrils (<xref ref-type="bibr" rid="bib31">Hubmacher and Apte, 2015</xref>; <xref ref-type="bibr" rid="bib2">Bader et al., 2010</xref>; <xref ref-type="bibr" rid="bib3">Bader et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Gabriel et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Le Goff et al., 2008</xref>; <xref ref-type="bibr" rid="bib74">Saito et al., 2011</xref>; <xref ref-type="bibr" rid="bib83">Tsutsui et al., 2010</xref>). ADAMTS10, if furin-activated by introduction of a furin cleavage site, was recently demonstrated to be proteolytically active against fibrillin-2 (<xref ref-type="bibr" rid="bib85">Wang et al., 2019a</xref>), suggesting that the small fraction of ADAMTS10 that underwent activation could cleave fibrillin-2, and indeed, persistent fibrillin-2 fibrils were seen in <italic>Adamts10</italic>-deficient mice, which are viable to adulthood. The present work shows that ADAMTS6, whose zymogen is efficiently activated by furin (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>), cleaves both monomeric fibrillin-1 and fibrillin-2, and has identified specific sites of cleavage of these substrates using TAILS and validated proteolysis biochemically in the case of the fibrillin-2 cleavage site. Fibrillin microfibril proteolysis was supported by loss of fibrillin-2 and fibrillin-1 microfibrils assembled by <italic>Fbn1</italic><sup>-/-</sup> and <italic>Fbn2</italic><sup>-/-</sup> fibroblasts, respectively, in the presence of active ADAMTS6. Although we cannot exclude the possibility that ADAMTS6 acts via activation of another protease in the cell culture system that was used, the direct binding of ADAMTS6 to the fibrillins in a binary interaction assay strongly supports direct cleavage. The significance of reduced fibrillin-2 proteolysis and fibrillin-2 accumulation after <italic>Adamts6</italic> inactivation was demonstrated by dramatic reversal of the observed skeletal and palate defects after introducing <italic>Fbn2</italic> haploinsufficiency in <italic>Adamts6</italic> mutants. The lack of a comparable effect after reduction of fibrillin-1 suggested a primacy of the ADAMTS6-fibrillin-2 relationship. Although ADAMTS6 cleaves fibrillin-1, it is not as essential for proteolysis of fibrillin-1, presumably because other proteases potentially compensate. While we cannot exclude the likelihood of accumulation of additional ADAMTS6 proteolytic targets in the skeleton, such as LTBP-1, which it was previously shown to cleave (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>), the present work strongly suggests that fibrillin-2 proteolysis by ADAMTS6 is necessary for proper skeletogenesis.</p><p>In addition to mechanical effects of excess perichondrial fibrillin-2 on cartilage that could affect skeletal development, reduced fibrillin-2 proteolysis could lead to dysregulated sequestration and release of growth factors of the TGFβ superfamily, since fibrillin-2 can bind to numerous superfamily members including several BMPs and GDFs (<xref ref-type="bibr" rid="bib78">Sengle et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Gregory et al., 2005</xref>; <xref ref-type="bibr" rid="bib77">Sengle et al., 2011</xref>). Fibrillin microfibrils appear to have little role in activation of the BMPs, and primarily affect their local concentrations and release, for example, by BMP cleavage, which was recently attributed to MMPs (<xref ref-type="bibr" rid="bib24">Furlan et al., 2021</xref>; <xref ref-type="bibr" rid="bib87">Wohl et al., 2016</xref>). In contrast, proteolysis of fibrillins was not previously implicated in control of local BMP/GDF activity. In the present work, the microfibril changes in the perichondrium were associated with changes in the underlying cartilage, in further support of phenotype modulation across the perichondrium-cartilage boundary (<xref ref-type="bibr" rid="bib12">Colnot et al., 2005</xref>; <xref ref-type="bibr" rid="bib47">Maes, 2017</xref>; <xref ref-type="bibr" rid="bib84">Vortkamp et al., 1996</xref>). Prior work has shown that combinations of TGFβ superfamily members strongly promote expression of typical cartilage genes (<xref ref-type="bibr" rid="bib60">Murphy et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Hatakeyama et al., 2004</xref>). This previous work together with the observed reduction in pSmad5 levels (indicative of reduced BMP signaling) may explain reduced Sox9, aggrecan and link protein that we observed. The resulting reduced cartilage proteoglycan potentially results in softer cartilage that could be susceptible to angulation forces as limb muscles develop.</p><p>Consistent with the conclusion that <italic>Adamts6</italic> deficiency reduces limb cartilage BMP signaling as a result of excess fibrillin-2, <italic>Fbn2</italic>-deficent mice have increased BMP signaling (<xref ref-type="bibr" rid="bib78">Sengle et al., 2015</xref>). Thus, accumulation of fibrillin-2 microfibrils resulting from combined ADAMTS6 and ADAMTS10 deficiency may excessively sequester BMPs and GDFs in the perichondrium, leading to impaired BMP signaling in the underlying cartilage (<xref ref-type="fig" rid="fig11">Figure 11</xref>). Fibrillins interact with the related latent TGFβ-binding proteins and furthermore, MAGP1, a fibrillin-binding partner shown to accumulate in the <italic>Adamts6</italic> mutant mice, also regulates the cellular microenvironment via growth factor binding (<xref ref-type="bibr" rid="bib57">Miyamoto et al., 2006</xref>; <xref ref-type="bibr" rid="bib64">Nehring et al., 2005</xref>). Moreover, ADAMTS6-mediated proteolysis of cell-surface heparan-sulfate proteoglycans (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>) could also influence the skeletal microenvironment. However, although such complex effects on diverse soluble morphogens and growth factors may ensue downstream of the observed ECM changes, the genetic evidence from our studies unequivocally indicates that fibrillin-2 accumulation is a central mechanism underlying the skeletal defects observed in the <italic>Adamts6</italic> mutant limbs. Thus, the present work highlights the significance of specific proteolytic mechanisms in fibrillin microfibril proteostasis, their importance for morphogen/growth factor regulation by ECM and ultimately, for cellular regulation by ECM.</p><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>Schematic illustrating the observed anomalies in the absence of ADAMTS6 and proposed roles and mechanisms of ADAMTS6 in skeletal development.</title><p>(<bold>A</bold>) <italic>Adamts6</italic> expression (pink dots) is shown in the perichondrium, peripheral chondrocytes, and in mesenchyme surrounding the knee joint. BMP signaling (blue circles) is evident in growth plate cartilage while fibrillin-2 (purple rods) and BMP/GDF (orange dots) are co-localized in the mesenchyme surrounding the knee joint and long bones. <italic>Adamts6</italic>-deficient limbs have a reduction of BMP signaling in the growth plate, retention of fibrillin-2 microfibrils and sequestration of GDF5, and presumably, other known fibrillin-2 binding BMPs/GDFs. (<bold>B</bold>) The schematic shows that in wild type limbs, ADAMTS6 cleaves fibrillin-2, allowing release of growth factors and contributing to proper cartilage growth and development. In the absence of ADAMTS6, there is an over-abundance of fibrillin-2 microfibrils, sequestration of GDF5/BMPs and as a consequence, reduced Sox9, aggrecan (blue shading) and cartilage link protein, impairing cartilage differentiation and structural integrity. Mechanistically, we conclude from the data that ADAMTS6 acts principally via fibrillin-2 cleavage and release of sequestered BMP/GDF. RZ, resting zone; CZ, columnar zone; HZ, hypertrophic zone; N, N-terminus; C, C-terminus of fibrillin-2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-71142-fig11-v1.tif"/><permissions><copyright-statement>© 2022, Cleveland Clinic Foundation. All Rights Reserved</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Cleveland Clinic Foundation</copyright-holder><license><license-p>Figure 11 is reprinted with permission from the Cleveland Clinic Foundation. Further reproduction of this figure would need permission from the copyright holder.</license-p></license></permissions></fig></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="center" valign="bottom">Designation</th><th align="center" valign="bottom">Source or reference</th><th align="center" valign="bottom">Identifiers</th><th align="center" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Adamts6</italic></td><td align="center" valign="bottom"> Genbank</td><td align="center" valign="bottom"> NCBI Gene: 108,154</td><td align="center" valign="bottom"> ADAM metallopeptidase with thrombospondin type 1 motif 6</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Adamts10</italic></td><td align="center" valign="bottom"> Genbank</td><td align="center" valign="bottom"> NCBI Gene: 224,697</td><td align="center" valign="bottom"> ADAM metallopeptidase with thrombospondin type 1 motif 10</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Adamts17</italic></td><td align="center" valign="bottom"> Genbank</td><td align="center" valign="bottom"> NCBI Gene: 233,332</td><td align="center" valign="bottom"> ADAM metallopeptidase with thrombospondin type 1 motif 17</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Adamts19</italic></td><td align="center" valign="bottom"> Genbank</td><td align="center" valign="bottom"> NCBI Gene: 240,322</td><td align="center" valign="bottom"> ADAM metallopeptidase with thrombospondin type 1 motif 19</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Fbn1</italic></td><td align="center" valign="bottom"> Genbank</td><td align="center" valign="bottom"> NCBI Gene: 14,118</td><td align="center" valign="bottom"> Fibrillin-1</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Fbn2</italic></td><td align="center" valign="bottom"> Genbank</td><td align="center" valign="bottom"> NCBI Gene: 14,119</td><td align="center" valign="bottom"> Fibrillin-2</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Fn1</italic></td><td align="center" valign="bottom"> Genbank</td><td align="center" valign="bottom"> NCBI Gene: 14,268</td><td align="center" valign="bottom"> Fibronectin</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Adamts6</italic><sup>b2b2029Clo</sup> (C57BL/6 J)</td><td align="center" valign="bottom"> Mouse Genome Informatics</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:5487397">MGI:5487397</ext-link></td><td align="center" valign="bottom"> <italic>Adamts6</italic> null allele</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Adamts10</italic><sup>tm1Dgen</sup> (C57BL/6 J)</td><td align="center" valign="bottom"> Mouse Genome Informatics</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:6355992">MGI:6355992</ext-link></td><td align="center" valign="bottom"> <italic>Adamts10</italic> null allele</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Fbn1</italic><sup>tm2Rmz</sup> (C57BL/6 J)</td><td align="center" valign="bottom"> Mouse Genome Informatics</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:1934906">MGI:1934906</ext-link></td><td align="center" valign="bottom"> <italic>Fbn1</italic><sup>mgR</sup> allele</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Fbn2</italic><sup>tm1Rmz</sup> (C57BL/6 J)</td><td align="center" valign="bottom"> Mouse Genome Informatics</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3652417">MGI:3652417</ext-link></td><td align="center" valign="bottom"> <italic>Fbn2</italic> null allele</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Fbn1</italic><sup>tm3Rmz</sup> (C57BL/6 J)</td><td align="center" valign="bottom"> PMCID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875392/">PMC3875392</ext-link></td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3641232">MGI:3641232</ext-link></td><td align="center" valign="bottom"> <italic>Fbn1</italic> null allele MEFs used for cell culture experiments</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Fbn2</italic><sup>tm1Rmz</sup> (C57BL/6 J)</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3652417">MGI:3652417</ext-link></td><td align="center" valign="bottom"> <italic>Fbn2</italic> null MEFs used for in vitro microfibril staining</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> C57BL/6 J strain</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="center" valign="bottom"> Wild type MEFs used for in vitro microfibril staining</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> <italic>Adamts6</italic><sup>b2b2029Clo</sup> (C57BL/6 J)</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:5487397">MGI:5487397</ext-link></td><td align="center" valign="bottom"> <italic>Adamts6</italic> mutant MEFs for in vitro microfibril staining</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> ADAMTS6 WT</td><td align="center" valign="bottom"> PMCID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048820/">PMC6048820</ext-link></td><td align="center" valign="bottom"/><td align="center" valign="bottom"> ADAMTS6 plasmid</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Mus musculus</italic>)</td><td align="center" valign="bottom"> ADAMTS6 EA</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom"> Catalytically- inactive ADAMTS6 plasmid</td></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="center" valign="bottom"> FBN1-expressing cells</td><td align="center" valign="bottom"> Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom"> Stable HEK293 cell line expressing full length FBN1</td></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="center" valign="bottom"> FBN2-Nt-expressing cells</td><td align="center" valign="bottom"> Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom"> Stable HEK293 cell line expressing the N-terminal half of FBN2</td></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="center" valign="bottom"> FBN2-Ct-expressing cells</td><td align="center" valign="bottom"> Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom"> Stable HEK293 cell line expressing the C-terminal half of FBN2</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">FBN2-Nt-expressing cells</td><td align="center" valign="bottom">Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> rFBN2-N; PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">FBN2-Ct</td><td align="center" valign="bottom">Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> rFBN2-C; PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">FBN1-Nt</td><td align="center" valign="bottom">Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> rFBN1-N; PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">FBN1-Ct</td><td align="center" valign="bottom">Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> rFBN1-C; PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">FN1</td><td align="center" valign="bottom">Deane Mosher, M.D.</td><td align="center" valign="bottom"> PMD:6133865</td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">ADAMTS6-Ct</td><td align="center" valign="bottom">Stuart Cain, Ph.D.</td><td align="center" valign="bottom"> PMCID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3=5078793/">PMC5078793</ext-link></td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">ADAMTS6-4TSR</td><td align="center" valign="bottom">Stuart Cain, Ph.D.</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">ADAMTS6-S4TSR</td><td align="center" valign="bottom">Stuart Cain, Ph.D.</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="center" valign="bottom">ADAMTS6-TCS</td><td align="center" valign="bottom">Stuart Cain, Ph.D.</td><td align="center" valign="bottom"> This paper</td><td align="center" valign="bottom">Used for Biacore analysis</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom">Anti-Fibrillin-2-Gly(rabbit polyclonal)</td><td align="center" valign="bottom">Robert Mecham, Ph.D.</td><td align="center" valign="bottom"> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10825173/">10825173</ext-link></td><td align="center" valign="bottom">IF (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-mFbn1-C (rabbit polyclonal)</td><td align="center" valign="bottom">Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/33039488/">33039488</ext-link></td><td align="center" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-rFBN2-C (rabbit polyclonal)</td><td align="center" valign="bottom">Dieter Reinhardt, Ph.D.</td><td align="center" valign="bottom"> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12399449/">12399449</ext-link></td><td align="center" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-MAGP1 (rabbit polyclonal)</td><td align="center" valign="bottom">Robert Mecham, Ph.D.</td><td align="center" valign="bottom"> PMCID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC14862/">PMC14862</ext-link></td><td align="center" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-Sox9 (rabbit polyclonal)</td><td align="center" valign="bottom"> Millipore AB5535</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2239761">AB_2239761</ext-link></td><td align="center" valign="bottom"> IF (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-Acan (rabbit polyclonal)</td><td align="center" valign="bottom"> Millipore AB1031</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_90460">AB_90460</ext-link></td><td align="center" valign="bottom"> IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-CLP (mouse monoclonal)</td><td align="center" valign="bottom"> DSHB 9/30/8 A-4</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2248142">AB_2248142</ext-link></td><td align="center" valign="bottom"> IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-Col X (rabbit polyclonal)</td><td align="center" valign="bottom"> Abcam ab58632</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_879742">AB_879742</ext-link></td><td align="center" valign="bottom"> IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-PCNA (mouse monoclonal)</td><td align="center" valign="bottom"> Cell Signaling 2,586</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2160343">AB_2160343</ext-link></td><td align="center" valign="bottom"> IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-His (mouse monoclonal)</td><td align="center" valign="bottom"> R&amp;D MAB050</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_357353">AB_357353</ext-link></td><td align="center" valign="bottom"> IF (1:400) WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-pSmad5 (rabbit polyclonal)</td><td align="center" valign="bottom"> Abcam ab92698</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10561456">AB_10561456</ext-link></td><td align="center" valign="bottom"> WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-pSmad1/5 (rabbit polyclonal)</td><td align="center" valign="bottom"> Cell Signaling 9,516</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_491015">AB_491015</ext-link></td><td align="center" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom">Anti-pSmad2(rabbit polyclonal)</td><td align="center" valign="bottom"> Cell Signaling 3,108</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_490941">AB_490941</ext-link></td><td align="center" valign="bottom">IF (1:200)WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-GDF5 (goat polyclonal)</td><td align="center" valign="bottom"> R&amp;D AF853</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_355662">AB_355662</ext-link></td><td align="center" valign="bottom"> IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="center" valign="bottom"> Anti-GAPDH (mouse monoclonal)</td><td align="center" valign="bottom">Millipore MAB374</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2107445">AB_2107445</ext-link></td><td align="center" valign="bottom"> WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom"> <italic>Adamts6</italic> RNAscope probe</td><td align="center" valign="bottom"> ACD Bio</td><td align="center" valign="bottom"> 428,301</td><td align="center" valign="bottom">Mouse ISH probe</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom"> <italic>Adamts10</italic> RNAscope probe</td><td align="center" valign="bottom"> ACD Bio</td><td align="center" valign="bottom"> 585,161</td><td align="center" valign="bottom">Mouse ISH probe</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom"> RNAscope 2.5 HD Red in situ detection kit</td><td align="center" valign="bottom"> ACD Bio</td><td align="center" valign="bottom"> 322,350</td><td align="center" valign="bottom">Used to detect <italic>Adamts6</italic> and <italic>Adamts10</italic> probes</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="center" valign="bottom"> GraphPad Prism</td><td align="center" valign="bottom"> GraphPad</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="center" valign="bottom"> Utilized for statistical computing of data</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="center" valign="bottom"> Fiji</td><td align="center" valign="bottom"> NIH</td><td align="center" valign="bottom"> RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link></td><td align="center" valign="bottom">Used to quantify IF tissue sections</td></tr></tbody></table><table-wrap-foot><fn><p>IF, Immunofluorescence.; WB, western blot.; ISH, in situ hybridization.</p></fn></table-wrap-foot></table-wrap><sec id="s4-1"><title>Transgenic mice</title><p><italic>Adamts6</italic><sup>b2b2029Clo</sup> (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:5487287">MGI:5487287</ext-link>), <italic>Adamts10</italic><sup>tm1Dgen</sup> (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:6355992">MGI:6355992</ext-link>), <italic>Fbn1</italic><sup>mgR</sup> (<italic>Fbn1</italic><sup>tm2Rmz</sup>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:1934906">MGI:1934906</ext-link>) and <italic>Fbn2</italic><sup>tm1Rmz</sup> (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3652417">MGI:3652417</ext-link>) mice were previously described (<xref ref-type="bibr" rid="bib1">Arteaga-Solis et al., 2001</xref>; <xref ref-type="bibr" rid="bib85">Wang et al., 2019a</xref>; <xref ref-type="bibr" rid="bib67">Prins et al., 2018</xref>; <xref ref-type="bibr" rid="bib66">Pereira et al., 1999</xref>; <xref ref-type="bibr" rid="bib45">Li et al., 2015</xref>) and maintained on a C57BL/6 J background. All mouse experiments were approved by the Cleveland Clinic Institutional Animal Care and Use Committee (protocol 2018–2450).</p></sec><sec id="s4-2"><title>Histology and immunofluorescence microscopy</title><p>Forelimbs and hindlimbs were fixed with 4% paraformaldehyde (PFA) in PBS at 4 °C for 48 hr. 7 μm sections were used for histochemistry (alcian blue or RGB trichrome stain <xref ref-type="bibr" rid="bib26">Gaytan et al., 2020</xref>) or for indirect immunofluorescence. The primary antibodies (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) were followed by secondary goat anti-mouse or goat anti-rabbit antibody (A11004 or A11008; 1:400; Invitrogen, Thousand Oaks, CA) treatment. Prior to immunofluorescence, citrate antigen retrieval, immersion of slides in citrate-EDTA buffer (10 mM/l citric acid, 2 mM/l EDTA, 0.05% v/v Tween-20, pH 6.2) and microwaving for 4 intervals of 1.5 min at 50% power in a microwave oven with 30 s intervals between heating cycles, was utilized. In addition, hyaluronidase treatment of sections (0.2% in PBS; H-2251; Sigma) was used prior to fibrillin-2 and fibrillin-1 immunostaining. After depariffinization and rehydration, sections were stained with 1% alcian blue 8 GX (A3157; Sigma) in 3% acetic acid (pH 2.5) for 10 min, rinsed in tap water, counter-stained in nuclear fast red (J61010; Alfa Aesar) for 1 min, rinsed in tap water prior to dehydration and mounted as previously described (<xref ref-type="bibr" rid="bib51">Mead and Yutzey, 2009</xref>). RGB-trichrome staining was done essentially as previously described (<xref ref-type="bibr" rid="bib26">Gaytan et al., 2020</xref>). Briefly, after de-paraffinization and rehydration, the sections were stained with 1% alcian blue 8 GX (A3157; Sigma) in 3% acetic acid (pH 2.5) for 20 min, rinsed in tap water, 1% fast green FCF (F-99; Fisher Scientific) for 20 min, rinsed in tap water, 0.1% sirius red in saturated picric acid (26357–02; EMS) for 60 min, rinsed in 2 changes of 1% acetic acid prior to dehydration in 100% ethanol and xylene. TUNEL assay (11684795910; Sigma) was performed as described previously (<xref ref-type="bibr" rid="bib26">Gaytan et al., 2020</xref>). Images were obtained using an Olympus BX51 microscope with Leica DFC 7000T camera and Leica Application Suite V4.6 software (Leica, Wetzlar, Germany). Histological sections were masked during data collection and quantified utilizing NIH Fiji software (<xref ref-type="bibr" rid="bib75">Schindelin et al., 2012</xref>).</p><p>Alizarin red-alcian blue stained skeleton preparations were performed as described (<xref ref-type="bibr" rid="bib54">Mead, 2020a</xref>). Briefly, skinned, eviscerated mice were fixed in 80% ethanol for 24 hr, dehydrated in 95% ethanol for 24 hr and acetone for 48 hr, stained (0.1% alizarin red S, 0.3% alcian blue, 1% glacial acetic acid in 95% ethanol) for 48 hr, cleared in 95% ethanol for 1 hr, muscle tissue was gently removed with forceps, and the preparations were cleared in a series of increasing (20–80%) glycerol/1% KOH ratio until storage in 100% glycerin and photography (Leica MZ6; Insight Spot software camera and software). Crown to rump or individual bone length measurements were masked during data collection utilizing NIH Fiji software (<xref ref-type="bibr" rid="bib75">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-3"><title>RNA in situ hybridization (ISH)</title><p><italic>Adamts6</italic> and <italic>Adamts10</italic> ISH was performed using RNAscope (Advanced Cell Diagnostics, Newark, CA) as described (<xref ref-type="bibr" rid="bib55">Mead and Apte, 2020b</xref>). Briefly, 6 μm sections were deparaffinized and hybridized to mouse <italic>Adamts6</italic> and <italic>Adamts10</italic> probe sets (428301, 585161, respectively; Advanced Cell Diagnostics) using a HybEZ oven (Advanced Cell Diagnostics) and the RNAScope 2.5 HD Detection Reagent Kit (322360; Advanced Cell Diagnostics) and counterstained with eosin.</p></sec><sec id="s4-4"><title>Cell culture</title><p>HEK293F cells were purchased and authenticated from ATCC and maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C in 5% CO<sub>2</sub> using a humidified chamber. The cells were transiently transfected with ADAMTS6 WT or ADAMTS6 EA expression plasmids using PEI MAX (24765; Polysciences) and were co-cultured with <italic>Fbn1</italic><sup>-/-</sup> mouse embryo fibroblasts MEFs, prepared from <italic>Fbn1</italic><sup>tm3Rmz</sup> homozygous mutants (<xref ref-type="bibr" rid="bib9">Carta et al., 2006</xref>; <xref ref-type="bibr" rid="bib4">Beene et al., 2013</xref>) or <italic>Fbn2</italic><sup>-/-</sup> mouse skin fibroblasts (MSFs) (<xref ref-type="bibr" rid="bib4">Beene et al., 2013</xref>) in a 1:1 ratio on 8-well culture slides (354118; Falcon). Similarily, <italic>Adamts6</italic><sup>-/-</sup> and wild type MEFs were plated on 8-well culture slides for immunofluorescent staining. The cells were cultured for 6 days, fixed in ice-cold 70% methanol/30% acetone for 5 min at room temperature, blocked with 5% normal goat serum in PBS for 1 hr at room temperature and incubated with primary antibody (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) overnight at 4 °C as described (<xref ref-type="bibr" rid="bib32">Hubmacher et al., 2017</xref>). The cells were washed three times with PBS for 5 min at room temperature and incubated with Alexa-Fluor labeled secondary antibodies (goat anti-mouse 568 or goat anti-rabbit 488; Invitrogen A11004, A11008, respectively, 1:400).</p></sec><sec id="s4-5"><title>RNA isolation and quantitative real-time PCR (qRT-PCR)</title><p>Mouse hindlimbs, hearts and lungs were snap-frozen and stored at –80 °C until use. Total RNA was isolated using TRIzol (15596018, Invitrogen), and 2 μg of RNA was reverse transcribed into cDNA using a High-Capacity cDNA reverse transcription kit following the manufacturer’s instructions (4368814; Applied Biosystems, Foster City, CA). qRT-PCR was performed with Bullseye EvaGreen qPCR MasterMix (BEQPCR-S; MIDSCI) using an Applied Biosystems 7,500 instrument. The experiments were performed with three independent biological samples and reproducibility was confirmed with two to three technical replicates. <italic>Gapdh</italic> was used as a control for mRNA quantity. The ∆∆Ct method was used to calculate relative mRNA expression levels of target genes and shown as standard error of the mean (SEM). See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for primer sequences.</p></sec><sec id="s4-6"><title>Surface plasmon resonance analysis</title><p>The human fibrillin-2 recombinant halves (rFBN2-N and rFBN2-C, termed FBN2-Nt and FBN2-Ct in this manuscript, respectively) were purified to homogeneity (&gt; 90% purity) as described previously (<xref ref-type="bibr" rid="bib46">Lin et al., 2002</xref>). Recombinant human ADAMTS6-Ct (residues 558–1117), ADAMTS6-S4TSR (residues 717–1117), ADAMTS6-4TSR (residues 840–1117) and ADAMTS6-TCS (residues 558–839) were expressed using the mammalian expression vector pCEP-pu/AC7 modified with a C-terminal V5-His6 tag, in 293-EBNA cells as described previously (<xref ref-type="bibr" rid="bib8">Cain et al., 2016</xref>). Purified FBN2-Ct or ADAMTS6-Ct in 10 mM acetate, pH 4.0 were immobilized on a Biacore CM5 sensor chip (research grade) with the amine coupling kit following the manufacturer’s instructions (GE Healthcare). A total of 1700 resonance units of FBN2-Ct or ADAMTS6-Ct was coupled to the chip for analysis in a Biacore 3000 instrument (GE Healthcare). The kinetics analysis was performed at 25 °C in 10 mM Hepes buffer, pH 7.4 with 0.15 M NaCl, 2 mM CaCl<sub>2</sub>, and 0.005% or 0.05% (v/v) surfactant P20 at a flow rate of 30 μl/min. All the analytes were diluted in the above buffer at different concentrations and injected through an uncoupled control flow cell in series with the flow cell coupled with FBN2-Ct or ADAMTS6-Ct constructs. The sample injection time was 2 min for ADAMTS6 and 3 min for FBN2 analytes. The dissociation time was 10 min. 1 M ethanolamine, pH 8.5 was used for chip surface regeneration at a flow rate of 30 μl/min for 30–60 s followed by 2 min stabilization time. All data were corrected with reference to the background binding in the control flow cell. The association and disassociation curves were generated with the BIAevaluation software (version 4.0.1; GE Healthcare). The kinetic constants were calculated using the steady state affinity method. Similar experiments were performed with the human fibrillin-1 recombinant halves (rFBN1-N and rFBN1-C, termed FBN1-Nt and FBN1-Ct in this manuscript, respectively) (<xref ref-type="bibr" rid="bib46">Lin et al., 2002</xref>) with ADAMTS6-Ct.</p></sec><sec id="s4-7"><title>Site-directed mutagenesis, transient transfection, and western blotting</title><p>A plasmid encoding mouse ADAMTS6 with a C-terminal myc/his tag was generated previously (<xref ref-type="bibr" rid="bib67">Prins et al., 2018</xref>) and used for site-directed mutagenesis (Q5 Site-Directed Mutagenesis Kit; E0554; New England BioLabs) to introduce Ala at Glu<sup>404</sup>, a classic metalloprotease inactivating mutation (ADAMTS6 EA). Plasmids were transfected into HEK293F cells using PEI MAX (24765; Polysciences) and conditioned medium was collected 48–72 hr later. Aliquots of medium were analyzed by 7.5% reducing SDS-PAGE. Proteins were electroblotted to polyvinylidene fluoride membranes (IPFL00010, EMD Millipore, Billerica, MA), incubated with primary antibodies (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) overnight at 4 °C, followed by fluorescent secondary antibody goat anti mouse or rabbit (827–08365, 926–68170; 1:5000; Li-COR Biosciences, Lincoln, NE) for 1 hr at room temperature. Antibody binding was visualized using an ODYSSEY CLx infrared imaging system (LI-COR). For pSMAD2 and pSMAD5 detection, hindlimbs were placed in RIPA Buffer (ab156034; Abcam) and Complete Protease Inhibitor Cocktail (no 4693159001; Millipore) and PhosSTOP (Millipore no. 4906845001) were added prior to homogenization T10 basic ULTRA-TURRAX (IKA, Staufen, Germany) and ultrasonication (Qsonica, Newtown, CT, USA)(3 × 2 s at 20% with 3 s pause). The supernantant was collected after centrifugation and 100 μg loaded on a 10% gel. Western blot band intensity was quantified utilizing NIH Fiji software (<xref ref-type="bibr" rid="bib75">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-8"><title>Cell co-culture for degradomics</title><p>Transiently transfected HEK293F cells expressing wild type ADAMTS6 or ADAMTS6 EA were cocultured with HEK293F cells stably expressing either fibrillin-2 Ct or full-length fibrillin-1. To determine whether fibronectin was an ADAMTS6 substrate, HEK 293F cells were transiently transfected with either ADAMTS6 or ADAMTS6 EA plasmids and seeded onto wells coated with human fibronectin as previously described (<xref ref-type="bibr" rid="bib86">Wang et al., 2019b</xref>). These experiments used serum-free and phenol red-free DMEM.</p></sec><sec id="s4-9"><title>TAILS sample workflow</title><p>The conditioned medium from the above cell cultures were centrifuged at 4,000 rcf for 20 min at 4 °C and the supernatant was filtered through a 0.22 µM filter. The medium was concentrated 20-fold using a 3 kDa (Amicon) stirring filter. Proteins were isolated using chloroform/methanol precipitation and resuspended in 2.5 M GuHCl and 250 mM HEPES pH 7.8. Protein concentration was measured using the Bradford assay (Pierce, Thermo) to determine the volume needed for 500 µg of protein from each condition. Proteins were reduced with 10 mM dithiothreitol (DTT) for 30 min at 37 °C followed by alkylation with 20 mM N-ethylmaleimide in the dark for 20 min. The reaction was quenched by adding DTT to a final concentration of 20 mM. Proteins were labeled overnight with 40 mM light or heavy formaldehyde, which binds specifically to free N-termini and lysine residues (α and ε amines, respectively) in the presence of 20 mM sodium cyanoborohydride at 37 °C as described (<xref ref-type="bibr" rid="bib49">Martin et al., 2020</xref>). They were treated with an additional fresh 20 mM formaldehyde and 10 mM sodium cyanoborohydride for 2 hr the following day at 37 °C and the reaction was quenched with 100 mM Tris for 1 hr at 37 °C. 500 μg of each sample was combined for buffer exchange on a 3 kDa molecular weight cut-off column (EMD Millipore) into 100 mM ammonium bicarbonate and digested overnight at 37 °C with mass spectrometry grade trypsin gold (Promega) at a 1:50 trypsin:protein ratio. Peptides were eluted via centrifugation and 30 µg of this digest was reserved for pre-TAILS analysis. The remaining peptides underwent enrichment using hyperbranched polyglycerol-aldehyde polymers (HPG-ALD, Flintbox, <ext-link ext-link-type="uri" xlink:href="https://www.flintbox.com/public/project/1948/">https://www.flintbox.com/public/project/1948/</ext-link>) at a 5:1 polymer:protein ratio. HPG-ALD binds to unblocked (trypsin-generated) amino acid termini, excluding them from the sample and thus enriches for blocked/labeled N-termini (<xref ref-type="bibr" rid="bib41">Kockmann et al., 2016</xref>). The peptides were filtered through a 10 kDa MWCO column (EMD Millipore) to remove the polymer and obtain the TAILS fraction. TAILS and pre-TAILS fractions were desalted on a C18 Sep-Pak column (Waters) and eluted in 60:40 ACN: 1% trifluoroacetic acid. Samples were vacuum-centrifuged until dry and resuspended in 1% acetic acid for mass spectrometry.</p></sec><sec id="s4-10"><title>Mass spectrometry</title><p>Samples were analyzed on a ThermoFisher Scientific Fusion Lumos tribrid mass spectrometer system with a Thermo Ultimate 3,000 UHPLC interface. The HPLC column was a Dionex 15 cm x 75 µm internal diameter Acclaim Pepmap C18, 2 μm, 100 Å reversed- phase capillary chromatography column. Five μL volumes of the samples were injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.3 μL/min were introduced into the source of the mass spectrometer on-line over a 120 min gradient. The nanospray ion source was operated at 1.9 kV. The digest was analyzed using a data-dependent method with 35% collision-induced dissociation fragmentation of the most abundant peptides every 3 s and an isolation window of 0.7 m/z for ion-trap MS/MS. Scans were conducted at a maximum resolution of 120,000 for full MS. Dynamic exclusion was enabled with a repeat count of 1 and ions within 10 ppm of the fragmented mass were excluded for 60 s.</p></sec><sec id="s4-11"><title>Proteomics data analysis</title><p>Peptides were identified using a precursor mass tolerance of 10 ppm, and fragment mass tolerance of 0.6 Da. The only static modification was carbamidomethyl (C), whereas dynamic modifications included the light (28.03 Da) dimethyl formaldehyde (N-terminal, K), heavy (34.06) dimethyl formaldehyde (N-terminal, K), oxidation (M, P), deamidation (N), acetylation (N-terminal), and Gln to pyro-Glu N-terminal cyclization. Peptides were validated using a false discovery rate (FDR) of 1% against a decoy database. Only high-confidence proteins (containing peptides at a 99% confidence level or higher) were recorded from each sample for data analysis. Internal peptides were identified based on the criteria of having an N-terminal modification, and a sequence that does not begin prior to the third amino acid in the protein or immediately following a known signal, transit, or propeptide sequence. Peptides that met these criteria were further analyzed based on the average fold-change ratio (ADAMTS6 WT/ ADAMTS6 EA sample abundance) between the three technical replicate pairs. The internal peptide abundance was divided by the total protein abundance fold-change to account for differences in protein levels between groups. Peptides that met these criteria and contained a weighted ratio (ADAMTS6 WT/ ADAMTS6 EA) greater than 1 underwent a t-test for significance. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD027096 and 10.6019/PXD027096.</p></sec><sec id="s4-12"><title>Statistics</title><p>Representative data of three independent, biological replicates are reported unless otherwise indicated. The two-tailed, unpaired Student t-test was used to obtain p values. Asterisks indicate differences with statistical significance as follows: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. In the dimethyl-TAILS experiments a two-tailed, paired Student t-test was used to obtain p values. Asterisks indicate differences with statistical significance as follows: *p ≤ 0.01, <sup>#</sup> ≤ 0.05.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Formal analysis, Funding acquisition, Project administration, Supervision, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocol 2018-2450 at the Cleveland Clinic.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-71142-transrepform1-v1.docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Original, unedited western blots.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-71142-data1-v1.zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Antibodies.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-71142-supp1-v1.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Quantitative Real-Time PCR primers.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-71142-supp2-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset identifier PXD027096 and 10.6019/PXD027096&quot;.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Proteolysis of fibrillin-2 microfibrils is essential for normal skeletal development</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD027096">PXD027096</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the Allen Distinguished Investigator Program, through support made by The Paul G Allen Frontiers Group and the American Heart Association (to SSA), the National Institutes of Health (F32AR063548 and RO1HL156987 to TJM) and the David and Lindsay Morgenthaler Postdoctoral Fellowship (to TJM). DPR was supported by the Canadian Institutes of Health Research (PJT-162099) and the Marfan Foundation (USA). The Wellcome Centre for Cell-Matrix Research is supported by funding from Wellcome (203128/Z/16/Z). CB gratefully acknowledges BBSRC funding (Ref: BB/R008221/1). We thank Dr. Francesco Ramirez for <italic>Fbn1</italic> and <italic>Fbn2</italic> mutant mice, Dr. Deane Mosher for fibronectin and Dr. Robert Mecham for fibrillin-2 antibody.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arteaga-Solis</surname><given-names>E</given-names></name><name><surname>Gayraud</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Shum</surname><given-names>L</given-names></name><name><surname>Sakai</surname><given-names>L</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regulation of limb patterning by extracellular microfibrils</article-title><source>The Journal of Cell Biology</source><volume>154</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1083/jcb.200105046</pub-id><pub-id pub-id-type="pmid">11470817</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>HL</given-names></name><name><surname>Ruhe</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Wong</surname><given-names>AK</given-names></name><name><surname>Walsh</surname><given-names>KF</given-names></name><name><surname>Packer</surname><given-names>RA</given-names></name><name><surname>Mitelman</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>KR</given-names></name><name><surname>O’Brien</surname><given-names>DP</given-names></name><name><surname>Broman</surname><given-names>KW</given-names></name><name><surname>Shelton</surname><given-names>GD</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name><name><surname>Neff</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An ADAMTSL2 founder mutation causes Musladin-Lueke Syndrome, a heritable disorder of beagle dogs, featuring stiff skin and joint contractures</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e12817</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012817</pub-id><pub-id pub-id-type="pmid">20862248</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Ho</surname><given-names>JC</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Holden</surname><given-names>P</given-names></name><name><surname>Fitzgerald</surname><given-names>J</given-names></name><name><surname>Atit</surname><given-names>RP</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5) is A novel fibrillin-1-, fibrillin-2-, and heparin-binding member of the ADAMTS superfamily containing A netrin-like module</article-title><source>Matrix Biology</source><volume>31</volume><fpage>398</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2012.09.003</pub-id><pub-id pub-id-type="pmid">23010571</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beene</surname><given-names>LC</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Hubmacher</surname><given-names>D</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Annis</surname><given-names>DS</given-names></name><name><surname>Mosher</surname><given-names>DF</given-names></name><name><surname>Mecham</surname><given-names>RP</given-names></name><name><surname>Traboulsi</surname><given-names>EI</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nonselective assembly of fibrillin 1 and fibrillin 2 in the rodent ocular zonule and in cultured cells: implications for Marfan syndrome</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>54</volume><fpage>8337</fpage><lpage>8344</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-13121</pub-id><pub-id pub-id-type="pmid">24265020</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekhouche</surname><given-names>M</given-names></name><name><surname>Leduc</surname><given-names>C</given-names></name><name><surname>Dupont</surname><given-names>L</given-names></name><name><surname>Janssen</surname><given-names>L</given-names></name><name><surname>Delolme</surname><given-names>F</given-names></name><name><surname>Vadon-Le Goff</surname><given-names>S</given-names></name><name><surname>Smargiasso</surname><given-names>N</given-names></name><name><surname>Baiwir</surname><given-names>D</given-names></name><name><surname>Mazzucchelli</surname><given-names>G</given-names></name><name><surname>Zanella-Cleon</surname><given-names>I</given-names></name><name><surname>Dubail</surname><given-names>J</given-names></name><name><surname>De Pauw</surname><given-names>E</given-names></name><name><surname>Nusgens</surname><given-names>B</given-names></name><name><surname>Hulmes</surname><given-names>DJ</given-names></name><name><surname>Moali</surname><given-names>C</given-names></name><name><surname>Colige</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Determination of the substrate repertoire of ADAMTS2, 3, and 14 significantly broadens their functions and identifies extracellular matrix organization and TGF-beta signaling as primary targets</article-title><source>FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology</source><volume>30</volume><fpage>1741</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1096/fj.15-279869</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cain</surname><given-names>SA</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name><name><surname>Gallagher</surname><given-names>J</given-names></name><name><surname>Morgan</surname><given-names>A</given-names></name><name><surname>Bax</surname><given-names>DV</given-names></name><name><surname>Weiss</surname><given-names>AS</given-names></name><name><surname>Shuttleworth</surname><given-names>CA</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Fibrillin-1 interactions with heparin: Implications for microfibril and elastic fiber assembly</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>30526</fpage><lpage>30537</lpage><pub-id pub-id-type="doi">10.1074/jbc.M501390200</pub-id><pub-id pub-id-type="pmid">15980072</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cain</surname><given-names>SA</given-names></name><name><surname>Morgan</surname><given-names>A</given-names></name><name><surname>Sherratt</surname><given-names>MJ</given-names></name><name><surname>Ball</surname><given-names>SG</given-names></name><name><surname>Shuttleworth</surname><given-names>CA</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Proteomic analysis of fibrillin-rich microfibrils</article-title><source>Proteomics</source><volume>6</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1002/pmic.200401340</pub-id><pub-id pub-id-type="pmid">16302274</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cain</surname><given-names>SA</given-names></name><name><surname>Mularczyk</surname><given-names>EJ</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Massam-Wu</surname><given-names>T</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ADAMTS-10 and -6 differentially regulate cell-cell junctions and focal adhesions</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>35956</elocation-id><pub-id pub-id-type="doi">10.1038/srep35956</pub-id><pub-id pub-id-type="pmid">27779234</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carta</surname><given-names>L</given-names></name><name><surname>Pereira</surname><given-names>L</given-names></name><name><surname>Arteaga-Solis</surname><given-names>E</given-names></name><name><surname>Lee-Arteaga</surname><given-names>SY</given-names></name><name><surname>Lenart</surname><given-names>B</given-names></name><name><surname>Starcher</surname><given-names>B</given-names></name><name><surname>Merkel</surname><given-names>CA</given-names></name><name><surname>Sukoyan</surname><given-names>M</given-names></name><name><surname>Kerkis</surname><given-names>A</given-names></name><name><surname>Hazeki</surname><given-names>N</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fibrillins 1 and 2 perform partially overlapping functions during aortic development</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>8016</fpage><lpage>8023</lpage><pub-id pub-id-type="doi">10.1074/jbc.M511599200</pub-id><pub-id pub-id-type="pmid">16407178</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbonneau</surname><given-names>NL</given-names></name><name><surname>Dzamba</surname><given-names>BJ</given-names></name><name><surname>Ono</surname><given-names>RN</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Corson</surname><given-names>GM</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Fibrillins can co-assemble in fibrils, but fibrillin fibril composition displays cell-specific differences</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>2740</fpage><lpage>2749</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209201200</pub-id><pub-id pub-id-type="pmid">12429739</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbonneau</surname><given-names>NL</given-names></name><name><surname>Jordan</surname><given-names>CD</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Lee-Arteaga</surname><given-names>S</given-names></name><name><surname>Dietz</surname><given-names>HC</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Microfibril structure masks fibrillin-2 in postnatal tissues</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>20242</fpage><lpage>20251</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.087031</pub-id><pub-id pub-id-type="pmid">20404337</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colnot</surname><given-names>C</given-names></name><name><surname>de la Fuente</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>St-Jacques</surname><given-names>B</given-names></name><name><surname>Helms</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Indian hedgehog synchronizes skeletal angiogenesis and perichondrial maturation with cartilage development</article-title><source>Development (Cambridge, England)</source><volume>132</volume><fpage>1057</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1242/dev.01649</pub-id><pub-id pub-id-type="pmid">15689378</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corson</surname><given-names>GM</given-names></name><name><surname>Charbonneau</surname><given-names>NL</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Differential expression of fibrillin-3 adds to microfibril variety in human and avian, but not rodent, connective tissues</article-title><source>Genomics</source><volume>83</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2003.08.023</pub-id><pub-id pub-id-type="pmid">14962672</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagoneau</surname><given-names>N</given-names></name><name><surname>Benoist-Lasselin</surname><given-names>C</given-names></name><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Mégarbané</surname><given-names>A</given-names></name><name><surname>Alswaid</surname><given-names>A</given-names></name><name><surname>Dollfus</surname><given-names>H</given-names></name><name><surname>Alembik</surname><given-names>Y</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Legeai-Mallet</surname><given-names>L</given-names></name><name><surname>Cormier-Daire</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome</article-title><source>American Journal of Human Genetics</source><volume>75</volume><fpage>801</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1086/425231</pub-id><pub-id pub-id-type="pmid">15368195</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallas</surname><given-names>SL</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Bruder</surname><given-names>SP</given-names></name><name><surname>Saharinen</surname><given-names>J</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Mundy</surname><given-names>GR</given-names></name><name><surname>Bonewald</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo</article-title><source>Journal of Bone and Mineral Research</source><volume>15</volume><fpage>68</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2000.15.1.68</pub-id><pub-id pub-id-type="pmid">10646116</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Maria</surname><given-names>A</given-names></name><name><surname>Wilmarth</surname><given-names>PA</given-names></name><name><surname>David</surname><given-names>LL</given-names></name><name><surname>Bassnett</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proteomic Analysis of the Bovine and Human Ciliary Zonule</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>58</volume><fpage>573</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1167/iovs.16-20866</pub-id><pub-id pub-id-type="pmid">28125844</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubail</surname><given-names>J</given-names></name><name><surname>Aramaki-Hattori</surname><given-names>N</given-names></name><name><surname>Bader</surname><given-names>HL</given-names></name><name><surname>Nelson</surname><given-names>CM</given-names></name><name><surname>Katebi</surname><given-names>N</given-names></name><name><surname>Matuska</surname><given-names>B</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A new Adamts9 conditional mouse allele identifies its non-redundant role in interdigital web regression</article-title><source>Genesis (New York, N.Y</source><volume>52</volume><fpage>702</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1002/dvg.22784</pub-id><pub-id pub-id-type="pmid">24753090</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubail</surname><given-names>J</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Insights on ADAMTS proteases and ADAMTS-like proteins from mammalian genetics</article-title><source>Matrix Biology</source><volume>44–46</volume><fpage>24</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2015.03.001</pub-id><pub-id pub-id-type="pmid">25770910</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Brolosy</surname><given-names>MA</given-names></name><name><surname>Kontarakis</surname><given-names>Z</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Kuenne</surname><given-names>C</given-names></name><name><surname>Günther</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>N</given-names></name><name><surname>Kikhi</surname><given-names>K</given-names></name><name><surname>Boezio</surname><given-names>GLM</given-names></name><name><surname>Takacs</surname><given-names>CM</given-names></name><name><surname>Lai</surname><given-names>SL</given-names></name><name><surname>Fukuda</surname><given-names>R</given-names></name><name><surname>Gerri</surname><given-names>C</given-names></name><name><surname>Giraldez</surname><given-names>AJ</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic compensation triggered by mutant mRNA degradation</article-title><source>Nature</source><volume>568</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1064-z</pub-id><pub-id pub-id-type="pmid">30944477</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enomoto</surname><given-names>H</given-names></name><name><surname>Nelson</surname><given-names>CM</given-names></name><name><surname>Somerville</surname><given-names>RPT</given-names></name><name><surname>Mielke</surname><given-names>K</given-names></name><name><surname>Dixon</surname><given-names>LJ</given-names></name><name><surname>Powell</surname><given-names>K</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cooperation of two ADAMTS metalloproteases in closure of the mouse palate identifies a requirement for versican proteolysis in regulating palatal mesenchyme proliferation</article-title><source>Development (Cambridge, England)</source><volume>137</volume><fpage>4029</fpage><lpage>4038</lpage><pub-id pub-id-type="doi">10.1242/dev.050591</pub-id><pub-id pub-id-type="pmid">21041365</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Dollfus</surname><given-names>H</given-names></name><name><surname>Lyonnet</surname><given-names>S</given-names></name><name><surname>Alembik</surname><given-names>Y</given-names></name><name><surname>Mégarbané</surname><given-names>A</given-names></name><name><surname>Samples</surname><given-names>J</given-names></name><name><surname>Gorlin</surname><given-names>RJ</given-names></name><name><surname>Alswaid</surname><given-names>A</given-names></name><name><surname>Feingold</surname><given-names>J</given-names></name><name><surname>Le Merrer</surname><given-names>M</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Cormier-Daire</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2003">2003a</year><article-title>Clinical homogeneity and genetic heterogeneity in Weill-Marchesani syndrome</article-title><source>American Journal of Medical Genetics. Part A</source><volume>123A</volume><fpage>204</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.20289</pub-id><pub-id pub-id-type="pmid">14598350</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faivre</surname><given-names>L</given-names></name><name><surname>Gorlin</surname><given-names>RJ</given-names></name><name><surname>Wirtz</surname><given-names>MK</given-names></name><name><surname>Godfrey</surname><given-names>M</given-names></name><name><surname>Dagoneau</surname><given-names>N</given-names></name><name><surname>Samples</surname><given-names>JR</given-names></name><name><surname>Le Merrer</surname><given-names>M</given-names></name><name><surname>Collod-Beroud</surname><given-names>G</given-names></name><name><surname>Boileau</surname><given-names>C</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Cormier-Daire</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2003">2003b</year><article-title>In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome</article-title><source>Journal of Medical Genetics</source><volume>40</volume><fpage>34</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1136/jmg.40.1.34</pub-id><pub-id pub-id-type="pmid">12525539</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikawa</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Ohbayashi</surname><given-names>T</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>von Melchner</surname><given-names>H</given-names></name><name><surname>Iwasaka</surname><given-names>T</given-names></name><name><surname>Shiojima</surname><given-names>I</given-names></name><name><surname>Akama</surname><given-names>TO</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Latent TGF-β binding protein 2 and 4 have essential overlapping functions in microfibril development</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>43714</elocation-id><pub-id pub-id-type="doi">10.1038/srep43714</pub-id><pub-id pub-id-type="pmid">28252045</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlan</surname><given-names>AG</given-names></name><name><surname>Spanou</surname><given-names>CES</given-names></name><name><surname>Godwin</surname><given-names>ARF</given-names></name><name><surname>Wohl</surname><given-names>AP</given-names></name><name><surname>Zimmermann</surname><given-names>L-MA</given-names></name><name><surname>Imhof</surname><given-names>T</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name><name><surname>Sengle</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A new MMP-mediated prodomain cleavage mechanism to activate bone morphogenetic proteins from the extracellular matrix</article-title><source>FASEB Journal</source><volume>35</volume><elocation-id>e21353</elocation-id><pub-id pub-id-type="doi">10.1096/fj.202001264R</pub-id><pub-id pub-id-type="pmid">33629769</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>LAR</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Bader</surname><given-names>H</given-names></name><name><surname>Ho</surname><given-names>JC</given-names></name><name><surname>Majors</surname><given-names>AK</given-names></name><name><surname>Hollyfield</surname><given-names>JG</given-names></name><name><surname>Traboulsi</surname><given-names>EI</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ADAMTSL4, a secreted glycoprotein widely distributed in the eye, binds fibrillin-1 microfibrils and accelerates microfibril biogenesis</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>53</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-5955</pub-id><pub-id pub-id-type="pmid">21989719</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaytan</surname><given-names>F</given-names></name><name><surname>Morales</surname><given-names>C</given-names></name><name><surname>Reymundo</surname><given-names>C</given-names></name><name><surname>Tena-Sempere</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A novel RGB-trichrome staining method for routine histological analysis of musculoskeletal tissues</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>16659</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-74031-x</pub-id><pub-id pub-id-type="pmid">33028938</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>Analysis of Post-Translational Modifications and Proteolysis in Neuroscience</chapter-title><person-group person-group-type="editor"><name><surname>Grant</surname><given-names>J.E</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><source>Identification of Protease Substrates in Complex Proteomes by ITRAQ-TAILs on a Thermo Q Exactive Instrument In</source><publisher-loc>New York, NY</publisher-loc><publisher-name>Springer Science+Business Media</publisher-name><fpage>187</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-3472-0</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>KE</given-names></name><name><surname>Ono</surname><given-names>RN</given-names></name><name><surname>Charbonneau</surname><given-names>NL</given-names></name><name><surname>Kuo</surname><given-names>C-L</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Bächinger</surname><given-names>HP</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>27970</fpage><lpage>27980</lpage><pub-id pub-id-type="doi">10.1074/jbc.M504270200</pub-id><pub-id pub-id-type="pmid">15929982</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname><given-names>Y</given-names></name><name><surname>Tuan</surname><given-names>RS</given-names></name><name><surname>Shum</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Distinct functions of BMP4 and GDF5 in the regulation of chondrogenesis</article-title><source>Journal of Cellular Biochemistry</source><volume>91</volume><fpage>1204</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1002/jcb.20019</pub-id><pub-id pub-id-type="pmid">15048875</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubmacher</surname><given-names>D</given-names></name><name><surname>El-Hallous</surname><given-names>EI</given-names></name><name><surname>Nelea</surname><given-names>V</given-names></name><name><surname>Kaartinen</surname><given-names>MT</given-names></name><name><surname>Lee</surname><given-names>ER</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Biogenesis of extracellular microfibrils: Multimerization of the fibrillin-1 C terminus into bead-like structures enables self-assembly</article-title><source>PNAS</source><volume>105</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.0706335105</pub-id><pub-id pub-id-type="pmid">18448684</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubmacher</surname><given-names>D</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ADAMTS proteins as modulators of microfibril formation and function</article-title><source>Matrix Biology</source><volume>47</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2015.05.004</pub-id><pub-id pub-id-type="pmid">25957949</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubmacher</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Berardinelli</surname><given-names>SJ</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Willard</surname><given-names>B</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Haltiwanger</surname><given-names>RS</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Unusual life cycle and impact on microfibril assembly of ADAMTS17, a secreted metalloprotease mutated in genetic eye disease</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>41871</elocation-id><pub-id pub-id-type="doi">10.1038/srep41871</pub-id><pub-id pub-id-type="pmid">28176809</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huxley-Jones</surname><given-names>J</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name><name><surname>Robertson</surname><given-names>DL</given-names></name><name><surname>Boot-Handford</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The characterisation of six ADAMTS proteases in the basal chordate <italic>Ciona intestinalis</italic> provides new insights into the vertebrate ADAMTS family</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>37</volume><fpage>1838</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2005.03.009</pub-id><pub-id pub-id-type="pmid">15899586</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huxley-Jones</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>TK</given-names></name><name><surname>Beck</surname><given-names>C</given-names></name><name><surname>Toubaris</surname><given-names>G</given-names></name><name><surname>Robertson</surname><given-names>DL</given-names></name><name><surname>Boot-Handford</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2007">2007a</year><article-title>The evolution of the vertebrate metzincins; insights from <italic>Ciona intestinalis</italic> and <italic>Danio rerio</italic></article-title><source>BMC Evolutionary Biology</source><volume>7</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2148-7-63</pub-id><pub-id pub-id-type="pmid">17439641</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huxley-Jones</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>DL</given-names></name><name><surname>Boot-Handford</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2007">2007b</year><article-title>On the origins of the extracellular matrix in vertebrates</article-title><source>Matrix Biology: Journal of the International Society for Matrix Biology</source><volume>26</volume><fpage>2</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2006.09.008</pub-id><pub-id pub-id-type="pmid">17055232</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>SA</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Gibson</surname><given-names>MA</given-names></name><name><surname>Weiss</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Protein interaction studies of MAGP-1 with tropoelastin and fibrillin-1</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><elocation-id>e200</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.M104533200</pub-id><pub-id pub-id-type="pmid">11481325</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karoulias</surname><given-names>SZ</given-names></name><name><surname>Taye</surname><given-names>N</given-names></name><name><surname>Stanley</surname><given-names>S</given-names></name><name><surname>Hubmacher</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The ADAMTS/Fibrillin Connection: Insights into the Biological Functions of ADAMTS10 and ADAMTS17 and Their Respective Sister Proteases</article-title><source>Biomolecules</source><volume>10</volume><elocation-id>596</elocation-id><pub-id pub-id-type="doi">10.3390/biom10040596</pub-id><pub-id pub-id-type="pmid">32290605</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kettle</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Grundy</surname><given-names>G</given-names></name><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Downing</surname><given-names>AK</given-names></name><name><surname>Handford</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Defective calcium binding to fibrillin-1: consequence of an N2144S change for fibrillin-1 structure and function</article-title><source>Journal of Molecular Biology</source><volume>285</volume><elocation-id>e368</elocation-id><pub-id pub-id-type="doi">10.1006/jmbi.1998.2368</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinsey</surname><given-names>R</given-names></name><name><surname>Williamson</surname><given-names>MR</given-names></name><name><surname>Chaudhry</surname><given-names>S</given-names></name><name><surname>Mellody</surname><given-names>KT</given-names></name><name><surname>McGovern</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Shuttleworth</surname><given-names>CA</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fibrillin-1 microfibril deposition is dependent on fibronectin assembly</article-title><source>Journal of Cell Science</source><volume>121</volume><fpage>2696</fpage><lpage>2704</lpage><pub-id pub-id-type="doi">10.1242/jcs.029819</pub-id><pub-id pub-id-type="pmid">18653538</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleifeld</surname><given-names>O</given-names></name><name><surname>Doucet</surname><given-names>A</given-names></name><name><surname>auf dem Keller</surname><given-names>U</given-names></name><name><surname>Prudova</surname><given-names>A</given-names></name><name><surname>Schilling</surname><given-names>O</given-names></name><name><surname>Kainthan</surname><given-names>RK</given-names></name><name><surname>Starr</surname><given-names>AE</given-names></name><name><surname>Foster</surname><given-names>LJ</given-names></name><name><surname>Kizhakkedathu</surname><given-names>JN</given-names></name><name><surname>Overall</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1038/nbt.1611</pub-id><pub-id pub-id-type="pmid">20208520</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kockmann</surname><given-names>T</given-names></name><name><surname>Carte</surname><given-names>N</given-names></name><name><surname>Melkko</surname><given-names>S</given-names></name><name><surname>Keller</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2016">2016</year><chapter-title>Identification of Protease Substrates in Complex Proteomes by iTRAQ-TAILS on a Thermo Q Exactive Instrument</chapter-title><person-group person-group-type="editor"><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><source>Analysis of Post-Translational Modifications and Proteolysis in Neuroscience</source><publisher-loc>New York, NY</publisher-loc><publisher-name>Springer</publisher-name><fpage>187</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1007/7657_2015_92</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozel</surname><given-names>BA</given-names></name><name><surname>Mecham</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Elastic fiber ultrastructure and assembly</article-title><source>Matrix Biology: Journal of the International Society for Matrix Biology</source><volume>84</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2019.10.002</pub-id><pub-id pub-id-type="pmid">31669522</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutz</surname><given-names>WE</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Bader</surname><given-names>HL</given-names></name><name><surname>Majors</surname><given-names>AK</given-names></name><name><surname>Iwata</surname><given-names>K</given-names></name><name><surname>Traboulsi</surname><given-names>EI</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ADAMTS10 Protein Interacts with Fibrillin-1 and Promotes Its Deposition in Extracellular Matrix of Cultured Fibroblasts</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><elocation-id>e571</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.M111.231571</pub-id><pub-id pub-id-type="pmid">21402694</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Goff</surname><given-names>C</given-names></name><name><surname>Morice-Picard</surname><given-names>F</given-names></name><name><surname>Dagoneau</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Perrot</surname><given-names>C</given-names></name><name><surname>Crow</surname><given-names>YJ</given-names></name><name><surname>Bauer</surname><given-names>F</given-names></name><name><surname>Flori</surname><given-names>E</given-names></name><name><surname>Prost-Squarcioni</surname><given-names>C</given-names></name><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Ge</surname><given-names>G</given-names></name><name><surname>Greenspan</surname><given-names>DS</given-names></name><name><surname>Bonnet</surname><given-names>D</given-names></name><name><surname>Le Merrer</surname><given-names>M</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name><name><surname>Cormier-Daire</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation</article-title><source>Nature Genetics</source><volume>40</volume><fpage>1119</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1038/ng.199</pub-id><pub-id pub-id-type="pmid">18677313</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Klena</surname><given-names>NT</given-names></name><name><surname>Gabriel</surname><given-names>GC</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>AJ</given-names></name><name><surname>Lemke</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chatterjee</surname><given-names>B</given-names></name><name><surname>Devine</surname><given-names>W</given-names></name><name><surname>Damerla</surname><given-names>RR</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>San Agustin</surname><given-names>JT</given-names></name><name><surname>Thahir</surname><given-names>M</given-names></name><name><surname>Anderton</surname><given-names>S</given-names></name><name><surname>Lawhead</surname><given-names>C</given-names></name><name><surname>Vescovi</surname><given-names>A</given-names></name><name><surname>Pratt</surname><given-names>H</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Haynes</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>CL</given-names></name><name><surname>Eppig</surname><given-names>JT</given-names></name><name><surname>Reinholdt</surname><given-names>L</given-names></name><name><surname>Francis</surname><given-names>R</given-names></name><name><surname>Leatherbury</surname><given-names>L</given-names></name><name><surname>Ganapathiraju</surname><given-names>MK</given-names></name><name><surname>Tobita</surname><given-names>K</given-names></name><name><surname>Pazour</surname><given-names>GJ</given-names></name><name><surname>Lo</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Global genetic analysis in mice unveils central role for cilia in congenital heart disease</article-title><source>Nature</source><volume>521</volume><fpage>520</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1038/nature14269</pub-id><pub-id pub-id-type="pmid">25807483</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Tiedemann</surname><given-names>K</given-names></name><name><surname>Vollbrandt</surname><given-names>T</given-names></name><name><surname>Peters</surname><given-names>H</given-names></name><name><surname>Batge</surname><given-names>B</given-names></name><name><surname>Brinckmann</surname><given-names>J</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Homo- and heterotypic fibrillin-1 and -2 interactions constitute the basis for the assembly of microfibrils</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>50795</fpage><lpage>50804</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210611200</pub-id><pub-id pub-id-type="pmid">12399449</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Signaling pathways effecting crosstalk between cartilage and adjacent tissues: Seminars in cell and developmental biology: The biology and pathology of cartilage</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>62</volume><fpage>16</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2016.05.007</pub-id><pub-id pub-id-type="pmid">27180955</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marson</surname><given-names>A</given-names></name><name><surname>Rock</surname><given-names>MJ</given-names></name><name><surname>Cain</surname><given-names>SA</given-names></name><name><surname>Freeman</surname><given-names>LJ</given-names></name><name><surname>Morgan</surname><given-names>A</given-names></name><name><surname>Mellody</surname><given-names>K</given-names></name><name><surname>Shuttleworth</surname><given-names>CA</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Homotypic fibrillin-1 interactions in microfibril assembly</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><elocation-id>9200</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.M409029200</pub-id><pub-id pub-id-type="pmid">15569675</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DR</given-names></name><name><surname>Witten</surname><given-names>JC</given-names></name><name><surname>Tan</surname><given-names>CD</given-names></name><name><surname>Rodriguez</surname><given-names>ER</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Pettersson</surname><given-names>GB</given-names></name><name><surname>Seifert</surname><given-names>DE</given-names></name><name><surname>Willard</surname><given-names>BB</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteomics identifies a convergent innate response to infective endocarditis and extensive proteolysis in vegetation components</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>317</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.135317</pub-id><pub-id pub-id-type="pmid">32544089</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCulloch</surname><given-names>DR</given-names></name><name><surname>Nelson</surname><given-names>CM</given-names></name><name><surname>Dixon</surname><given-names>LJ</given-names></name><name><surname>Silver</surname><given-names>DL</given-names></name><name><surname>Wylie</surname><given-names>JD</given-names></name><name><surname>Lindner</surname><given-names>V</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Cooley</surname><given-names>MA</given-names></name><name><surname>Argraves</surname><given-names>WS</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ADAMTS metalloproteases generate active versican fragments that regulate interdigital web regression</article-title><source>Developmental Cell</source><volume>17</volume><elocation-id>e8</elocation-id><pub-id pub-id-type="doi">10.1016/j.devcel.2009.09.008</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>TJ</given-names></name><name><surname>Yutzey</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development</article-title><source>PNAS</source><volume>106</volume><fpage>14420</fpage><lpage>14425</lpage><pub-id pub-id-type="doi">10.1073/pnas.0902306106</pub-id><pub-id pub-id-type="pmid">19590010</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>TJ</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>ADAMTS proteins in human disorders</article-title><source>Matrix Biology: Journal of the International Society for Matrix Biology</source><volume>39</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.1016/j.matbio.2018.06.002</pub-id><pub-id pub-id-type="pmid">29885460</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>TJ</given-names></name><name><surname>McCulloch</surname><given-names>DR</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Adams</surname><given-names>SM</given-names></name><name><surname>Birk</surname><given-names>DE</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>The metalloproteinase-proteoglycans ADAMTS7 and ADAMTS12 provide an innate, tendon-specific protective mechanism against heterotopic ossification</article-title><source>JCI Insight</source><volume>3</volume><elocation-id>941</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.92941</pub-id><pub-id pub-id-type="pmid">29618652</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Alizarin Red and Alcian Blue Preparations to Visualize the Skeleton</article-title><source>Methods in Molecular Biology (Clifton, N.J.)</source><volume>2043</volume><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9698-8_17</pub-id><pub-id pub-id-type="pmid">31463914</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>TJ</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>In Situ Hybridization</article-title><source>Methods in Molecular Biology (Clifton, N.J.)</source><volume>2043</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9698-8_14</pub-id><pub-id pub-id-type="pmid">31463911</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mecham</surname><given-names>RP</given-names></name><name><surname>Gibson</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The microfibril-associated glycoproteins (MAGPs) and the microfibrillar niche</article-title><source>Matrix Biology</source><volume>47</volume><fpage>13</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2015.05.003</pub-id><pub-id pub-id-type="pmid">25963142</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>A</given-names></name><name><surname>Lau</surname><given-names>R</given-names></name><name><surname>Hein</surname><given-names>PW</given-names></name><name><surname>Shipley</surname><given-names>JM</given-names></name><name><surname>Weinmaster</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Microfibrillar proteins MAGP-1 and MAGP-2 induce Notch1 extracellular domain dissociation and receptor activation</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>10089</fpage><lpage>10097</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600298200</pub-id><pub-id pub-id-type="pmid">16492672</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>J</given-names></name><name><surname>Al-Sharif</surname><given-names>L</given-names></name><name><surname>Khalil</surname><given-names>DS</given-names></name><name><surname>Shinwari</surname><given-names>JMA</given-names></name><name><surname>Bavi</surname><given-names>P</given-names></name><name><surname>Al-Mahrouqi</surname><given-names>RA</given-names></name><name><surname>Al-Rajhi</surname><given-names>A</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Meyer</surname><given-names>BF</given-names></name><name><surname>Al Tassan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature</article-title><source>American Journal of Human Genetics</source><volume>85</volume><fpage>558</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2009.09.011</pub-id><pub-id pub-id-type="pmid">19836009</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mularczyk</surname><given-names>EJ</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Godwin</surname><given-names>ARF</given-names></name><name><surname>Galli</surname><given-names>F</given-names></name><name><surname>Humphreys</surname><given-names>N</given-names></name><name><surname>Adamson</surname><given-names>AD</given-names></name><name><surname>Mironov</surname><given-names>A</given-names></name><name><surname>Cain</surname><given-names>SA</given-names></name><name><surname>Sengle</surname><given-names>G</given-names></name><name><surname>Boot-Handford</surname><given-names>RP</given-names></name><name><surname>Cossu</surname><given-names>G</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ADAMTS10-mediated tissue disruption in Weill-Marchesani syndrome</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>3675</fpage><lpage>3687</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy276</pub-id><pub-id pub-id-type="pmid">30060141</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>MK</given-names></name><name><surname>Huey</surname><given-names>DJ</given-names></name><name><surname>Hu</surname><given-names>JC</given-names></name><name><surname>Athanasiou</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TGF-β1, GDF-5, and BMP-2 stimulation induces chondrogenesis in expanded human articular chondrocytes and marrow-derived stromal cells</article-title><source>Stem Cells (Dayton, Ohio)</source><volume>33</volume><fpage>762</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1002/stem.1890</pub-id><pub-id pub-id-type="pmid">25377511</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandadasa</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>CM</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ADAMTS9-Mediated Extracellular Matrix Dynamics Regulates Umbilical Cord Vascular Smooth Muscle Differentiation and Rotation</article-title><source>Cell Reports</source><volume>11</volume><fpage>1519</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.05.005</pub-id><pub-id pub-id-type="pmid">26027930</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandadasa</surname><given-names>S</given-names></name><name><surname>Kraft</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>O’Donnell</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Gee</surname><given-names>HY</given-names></name><name><surname>Grobe</surname><given-names>K</given-names></name><name><surname>Cox</surname><given-names>TC</given-names></name><name><surname>Hildebrandt</surname><given-names>F</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Secreted metalloproteases ADAMTS9 and ADAMTS20 have a non-canonical role in ciliary vesicle growth during ciliogenesis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>953</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08520-7</pub-id><pub-id pub-id-type="pmid">30814516</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandadasa</surname><given-names>S</given-names></name><name><surname>Burin des Roziers</surname><given-names>C</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Tran-Lundmark</surname><given-names>K</given-names></name><name><surname>Dours-Zimmermann</surname><given-names>MT</given-names></name><name><surname>Zimmermann</surname><given-names>DR</given-names></name><name><surname>Valleix</surname><given-names>S</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A new mouse mutant with cleavage-resistant versican and isoform-specific versican mutants demonstrate that proteolysis at the Glu<sup>441</sup>-Ala<sup>442</sup> peptide bond in the V1 isoform is essential for interdigital web regression</article-title><source>Matrix Biology Plus</source><volume>10</volume><elocation-id>100064</elocation-id><pub-id pub-id-type="doi">10.1016/j.mbplus.2021.100064</pub-id><pub-id pub-id-type="pmid">34195596</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nehring</surname><given-names>LC</given-names></name><name><surname>Miyamoto</surname><given-names>A</given-names></name><name><surname>Hein</surname><given-names>PW</given-names></name><name><surname>Weinmaster</surname><given-names>G</given-names></name><name><surname>Shipley</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The extracellular matrix protein MAGP-2 interacts with Jagged1 and induces its shedding from the cell surface</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>20349</fpage><lpage>20355</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500273200</pub-id><pub-id pub-id-type="pmid">15788413</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nistala</surname><given-names>H</given-names></name><name><surname>Lee-Arteaga</surname><given-names>S</given-names></name><name><surname>Smaldone</surname><given-names>S</given-names></name><name><surname>Siciliano</surname><given-names>G</given-names></name><name><surname>Carta</surname><given-names>L</given-names></name><name><surname>Ono</surname><given-names>RN</given-names></name><name><surname>Sengle</surname><given-names>G</given-names></name><name><surname>Arteaga-Solis</surname><given-names>E</given-names></name><name><surname>Levasseur</surname><given-names>R</given-names></name><name><surname>Ducy</surname><given-names>P</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Karsenty</surname><given-names>G</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation</article-title><source>The Journal of Cell Biology</source><volume>190</volume><fpage>1107</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1083/jcb.201003089</pub-id><pub-id pub-id-type="pmid">20855508</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Gayraud</surname><given-names>B</given-names></name><name><surname>Andrikopoulos</surname><given-names>K</given-names></name><name><surname>Shapiro</surname><given-names>SD</given-names></name><name><surname>Bunton</surname><given-names>T</given-names></name><name><surname>Biery</surname><given-names>NJ</given-names></name><name><surname>Dietz</surname><given-names>HC</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1</article-title><source>PNAS</source><volume>96</volume><fpage>3819</fpage><lpage>3823</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.7.3819</pub-id><pub-id pub-id-type="pmid">10097121</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>BP</given-names></name><name><surname>Mead</surname><given-names>TJ</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Sveinbjornsson</surname><given-names>G</given-names></name><name><surname>Ntalla</surname><given-names>I</given-names></name><name><surname>Bihlmeyer</surname><given-names>NA</given-names></name><name><surname>van den Berg</surname><given-names>M</given-names></name><name><surname>Bork-Jensen</surname><given-names>J</given-names></name><name><surname>Cappellani</surname><given-names>S</given-names></name><name><surname>Van Duijvenboden</surname><given-names>S</given-names></name><name><surname>Klena</surname><given-names>NT</given-names></name><name><surname>Gabriel</surname><given-names>GC</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gulec</surname><given-names>C</given-names></name><name><surname>Grarup</surname><given-names>N</given-names></name><name><surname>Haessler</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>LM</given-names></name><name><surname>Iorio</surname><given-names>A</given-names></name><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Li-Gao</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C-T</given-names></name><name><surname>Lyytikäinen</surname><given-names>L-P</given-names></name><name><surname>Marten</surname><given-names>J</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Müller-Nurasyid</surname><given-names>M</given-names></name><name><surname>Orini</surname><given-names>M</given-names></name><name><surname>Padmanabhan</surname><given-names>S</given-names></name><name><surname>Radmanesh</surname><given-names>F</given-names></name><name><surname>Ramirez</surname><given-names>J</given-names></name><name><surname>Robino</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>van Setten</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Verweij</surname><given-names>N</given-names></name><name><surname>Warren</surname><given-names>HR</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Arnar</surname><given-names>DO</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>de Boer</surname><given-names>RA</given-names></name><name><surname>Dominiczak</surname><given-names>AF</given-names></name><name><surname>Eijgelsheim</surname><given-names>M</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Heckbert</surname><given-names>SR</given-names></name><name><surname>Huang</surname><given-names>PL</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>Kähönen</surname><given-names>M</given-names></name><name><surname>Kors</surname><given-names>JA</given-names></name><name><surname>Lambiase</surname><given-names>PD</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Linneberg</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>CP</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name><name><surname>Perez</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Polasek</surname><given-names>O</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Raitakari</surname><given-names>OT</given-names></name><name><surname>Rice</surname><given-names>KM</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Sinner</surname><given-names>MF</given-names></name><name><surname>Soliman</surname><given-names>EZ</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Strauch</surname><given-names>K</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Tinker</surname><given-names>A</given-names></name><name><surname>Trompet</surname><given-names>S</given-names></name><name><surname>Uitterlinden</surname><given-names>A</given-names></name><name><surname>Vaartjes</surname><given-names>I</given-names></name><name><surname>van der Meer</surname><given-names>P</given-names></name><name><surname>Völker</surname><given-names>U</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Waldenberger</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Asselbergs</surname><given-names>FW</given-names></name><name><surname>Dörr</surname><given-names>M</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Gasparini</surname><given-names>P</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Kääb</surname><given-names>S</given-names></name><name><surname>Kanters</surname><given-names>JK</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Lehtimäki</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>HJ</given-names></name><name><surname>Lubitz</surname><given-names>SA</given-names></name><name><surname>Mook-Kanamori</surname><given-names>DO</given-names></name><name><surname>Conti</surname><given-names>FJ</given-names></name><name><surname>Newton-Cheh</surname><given-names>CH</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Rudan</surname><given-names>I</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Sinagra</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>BH</given-names></name><name><surname>Holm</surname><given-names>H</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name><name><surname>Ulivi</surname><given-names>S</given-names></name><name><surname>Sotoodehnia</surname><given-names>N</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name><name><surname>van der Harst</surname><given-names>P</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Munroe</surname><given-names>PB</given-names></name><name><surname>Arking</surname><given-names>DE</given-names></name><name><surname>Lo</surname><given-names>CW</given-names></name><name><surname>Jamshidi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>87</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1457-6</pub-id><pub-id pub-id-type="pmid">30012220</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>F</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Extracellular microfibrils: contextual platforms for TGFβ and BMP signaling</article-title><source>Current Opinion in Cell Biology</source><volume>21</volume><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2009.05.005</pub-id><pub-id pub-id-type="pmid">19525102</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>F</given-names></name><name><surname>Caescu</surname><given-names>C</given-names></name><name><surname>Wondimu</surname><given-names>E</given-names></name><name><surname>Galatioto</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Marfan syndrome; A connective tissue disease at the crossroads of mechanotransduction, TGFβ signaling and cell stemness</article-title><source>Matrix Biology</source><volume>71–72</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2017.07.004</pub-id><pub-id pub-id-type="pmid">28782645</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricard-Blum</surname><given-names>S</given-names></name><name><surname>Vallet</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fragments generated upon extracellular matrix remodeling: Biological regulators and potential drugs</article-title><source>Matrix Biology</source><volume>75–76</volume><fpage>170</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2017.11.005</pub-id><pub-id pub-id-type="pmid">29133183</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>PN</given-names></name><name><surname>Arteaga-Solis</surname><given-names>E</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name><name><surname>Collod-Béroud</surname><given-names>G</given-names></name><name><surname>Booms</surname><given-names>P</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name><name><surname>Dietz</surname><given-names>HC</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Handford</surname><given-names>PA</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name><name><surname>Kielty</surname><given-names>CM</given-names></name><name><surname>Loeys</surname><given-names>B</given-names></name><name><surname>Milewicz</surname><given-names>DM</given-names></name><name><surname>Ney</surname><given-names>A</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Tiedemann</surname><given-names>K</given-names></name><name><surname>Whiteman</surname><given-names>P</given-names></name><name><surname>Godfrey</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The molecular genetics of Marfan syndrome and related disorders</article-title><source>Journal of Medical Genetics</source><volume>43</volume><fpage>769</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1136/jmg.2005.039669</pub-id><pub-id pub-id-type="pmid">16571647</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Fagotto-Kaufmann</surname><given-names>C</given-names></name><name><surname>Hubmacher</surname><given-names>D</given-names></name><name><surname>McKee</surname><given-names>MD</given-names></name><name><surname>Annis</surname><given-names>DS</given-names></name><name><surname>Mosher</surname><given-names>DF</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fibrillin assembly requires fibronectin</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>846</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1091/mbc.E08-08-0830</pub-id><pub-id pub-id-type="pmid">19037100</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>L</given-names></name><name><surname>Miosge</surname><given-names>N</given-names></name><name><surname>Hubmacher</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>EC</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fibrillin-3 expression in human development</article-title><source>Matrix Biology</source><volume>30</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2010.10.003</pub-id><pub-id pub-id-type="pmid">20970500</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Kurokawa</surname><given-names>M</given-names></name><name><surname>Oda</surname><given-names>M</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Tsutsui</surname><given-names>K</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Nakao</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Manabe</surname><given-names>R-I</given-names></name><name><surname>Suda</surname><given-names>N</given-names></name><name><surname>Ganjargal</surname><given-names>G</given-names></name><name><surname>Hada</surname><given-names>Y</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Teranaka</surname><given-names>T</given-names></name><name><surname>Sekiguchi</surname><given-names>K</given-names></name><name><surname>Yoneda</surname><given-names>T</given-names></name><name><surname>Tsuji</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ADAMTSL6β protein rescues fibrillin-1 microfibril disorder in a Marfan syndrome mouse model through the promotion of fibrillin-1 assembly</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>38602</fpage><lpage>38613</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.243451</pub-id><pub-id pub-id-type="pmid">21880733</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengle</surname><given-names>G</given-names></name><name><surname>Charbonneau</surname><given-names>NL</given-names></name><name><surname>Ono</surname><given-names>RN</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Alvarez</surname><given-names>J</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Bächinger</surname><given-names>HP</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Targeting of bone morphogenetic protein growth factor complexes to fibrillin</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>13874</fpage><lpage>13888</lpage><pub-id pub-id-type="doi">10.1074/jbc.M707820200</pub-id><pub-id pub-id-type="pmid">18339631</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengle</surname><given-names>G</given-names></name><name><surname>Ono</surname><given-names>RN</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>5087</fpage><lpage>5099</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.188615</pub-id><pub-id pub-id-type="pmid">21135108</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengle</surname><given-names>G</given-names></name><name><surname>Carlberg</surname><given-names>V</given-names></name><name><surname>Tufa</surname><given-names>SF</given-names></name><name><surname>Charbonneau</surname><given-names>NL</given-names></name><name><surname>Smaldone</surname><given-names>S</given-names></name><name><surname>Carlson</surname><given-names>EJ</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Abnormal Activation of BMP Signaling Causes Myopathy in Fbn2 Null Mice</article-title><source>PLOS Genetics</source><volume>11</volume><elocation-id>e1005340</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1005340</pub-id><pub-id pub-id-type="pmid">26114882</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Yanagisawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Recent updates on the molecular network of elastic fiber formation</article-title><source>Essays in Biochemistry</source><volume>63</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1042/ebc20180052</pub-id><pub-id pub-id-type="pmid">31395654</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Somerville</surname><given-names>RPT</given-names></name><name><surname>Jungers</surname><given-names>KA</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Discovery and characterization of a novel, widely expressed metalloprotease, ADAMTS10, and its proteolytic activation</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>51208</fpage><lpage>51217</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409036200</pub-id><pub-id pub-id-type="pmid">15355968</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sztal</surname><given-names>TE</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptional adaptation: a mechanism underlying genetic robustness</article-title><source>Development (Cambridge, England)</source><volume>147</volume><elocation-id>6452</elocation-id><pub-id pub-id-type="doi">10.1242/dev.186452</pub-id><pub-id pub-id-type="pmid">32816903</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Eckersley</surname><given-names>A</given-names></name><name><surname>Cain</surname><given-names>SA</given-names></name><name><surname>Sherratt</surname><given-names>MJ</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fibrillin microfibrils and elastic fibre proteins: Functional interactions and extracellular regulation of growth factors</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>89</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2018.07.016</pub-id><pub-id pub-id-type="pmid">30016650</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsutsui</surname><given-names>K</given-names></name><name><surname>Manabe</surname><given-names>RI</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name><name><surname>Oguri</surname><given-names>Y</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Sengle</surname><given-names>G</given-names></name><name><surname>Sakai</surname><given-names>LY</given-names></name><name><surname>Sekiguchi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A disintegrin and metalloproteinase with thrombospondin motifs-like-6 (ADAMTSL-6) is A novel extracellular matrix protein that binds to fibrillin-1 and promotes fibrillin-1 fibril formation</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>4870</fpage><lpage>4882</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.076919</pub-id><pub-id pub-id-type="pmid">19940141</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vortkamp</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Lanske</surname><given-names>B</given-names></name><name><surname>Segre</surname><given-names>GV</given-names></name><name><surname>Kronenberg</surname><given-names>HM</given-names></name><name><surname>Tabin</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein</article-title><source>Science (New York, N.Y.)</source><volume>273</volume><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1126/science.273.5275.613</pub-id><pub-id pub-id-type="pmid">8662546</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Kutz</surname><given-names>WE</given-names></name><name><surname>Mead</surname><given-names>TJ</given-names></name><name><surname>Beene</surname><given-names>LC</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>MW</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Adamts10 inactivation in mice leads to persistence of ocular microfibrils subsequent to reduced fibrillin-2 cleavage</article-title><source>Matrix Biology</source><volume>77</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2018.09.004</pub-id><pub-id pub-id-type="pmid">30201140</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LW</given-names></name><name><surname>Nandadasa</surname><given-names>S</given-names></name><name><surname>Annis</surname><given-names>DS</given-names></name><name><surname>Dubail</surname><given-names>J</given-names></name><name><surname>Mosher</surname><given-names>DF</given-names></name><name><surname>Willard</surname><given-names>BB</given-names></name><name><surname>Apte</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>A disintegrin-like and metalloproteinase domain with thrombospondin type 1 motif 9 (ADAMTS9) regulates fibronectin fibrillogenesis and turnover</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>9924</fpage><lpage>9936</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.006479</pub-id><pub-id pub-id-type="pmid">31085586</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohl</surname><given-names>AP</given-names></name><name><surname>Troilo</surname><given-names>H</given-names></name><name><surname>Collins</surname><given-names>RF</given-names></name><name><surname>Baldock</surname><given-names>C</given-names></name><name><surname>Sengle</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Extracellular Regulation of Bone Morphogenetic Protein Activity by the Microfibril Component Fibrillin-1</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>12732</fpage><lpage>12746</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.704734</pub-id><pub-id pub-id-type="pmid">27059954</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>RKH</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Cheah</surname><given-names>KSE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanistic insights into skeletal development gained from genetic disorders</article-title><source>Current Topics in Developmental Biology</source><volume>133</volume><fpage>343</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/bs.ctdb.2019.02.002</pub-id><pub-id pub-id-type="pmid">30902258</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Apfelroth</surname><given-names>SD</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>EC</given-names></name><name><surname>Sanguineti</surname><given-names>C</given-names></name><name><surname>Bonadio</surname><given-names>J</given-names></name><name><surname>Mecham</surname><given-names>RP</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices</article-title><source>The Journal of Cell Biology</source><volume>124</volume><fpage>855</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1083/jcb.124.5.855</pub-id><pub-id pub-id-type="pmid">8120105</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Ramirez</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils</article-title><source>The Journal of Cell Biology</source><volume>129</volume><fpage>1165</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1083/jcb.129.4.1165</pub-id><pub-id pub-id-type="pmid">7744963</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71142.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schipani</surname><given-names>Ernestina</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>University of Pennsylvania</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.02.03.429587" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.02.03.429587"/></front-stub><body><p>The study proves that the in vivo genetic interaction between ADAMTS6 and fibrillin2 is critical for normal endochondral bone development. In particular, the authors show that global loss of ADAMTS6 causes a severe chondrodysplasia that is significantly worsened by concomitant loss of ADAMTS10 and, conversely, almost fully prevented by haploinsufficiency for fibrillin2, a substrate of ADAMTS6. The paper expands and deepens our current understanding of proteases and their substrates in endochondral bone development.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71142.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schipani</surname><given-names>Ernestina</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>University of Pennsylvania</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Lyons</surname><given-names>Karen</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>UCLA Orthopaedic Hospital</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.02.03.429587">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.02.03.429587v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Proteolysis of fibrillin-2 microfibrils is essential for normal skeletal development&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Kathryn Cheah as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Karen Lyons (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Numerous technical issues should be addressed to strengthen the authors' conclusions and their biological relevance.</p><p>Please, address reviewers' comments and concerns point-by-point.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. The analysis of the skull phenotype, including the cleft palate, is very superficial, incomplete and not properly developed. The authors should consider reporting the correct analysis of the skull in an independent manuscript.</p><p>2. Figure 1, supplement 5 is confusing and of poor quality. The authors should provide a systematic histological analysis at different time points and across all the genotypes. It is sufficient to focus exclusively on one skeletal element and systematically analyze it at different time points and in all the genotypes.</p><p>3. Along those lines, it would be useful to show whether the appearance of hypertrophy is delayed by loss of ADAMTS6, and this phenotype is worsened by concomitant loss of ADAMTS10.</p><p>4. Figure 2: Proper quantification of in situ data should be provided.</p><p>5. Figure 3: As above, proper quantification of immunofluorescence data should be provided.</p><p>6. Figure 4: Please, provide quantification.</p><p>7. Figure 4 , supplement 1: Please, provide quantification.</p><p>8. Figure 7: Please, provide quantification of in situ data.</p><p>9. It is critical to histologically document whether haploinsufficiency for fibrillin2 prevents the delay of endochondral bone development secondary to loss of ADAMTS6.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Figure 3 and Figure 4. Quantification of Fbn2 abundance (e.g. using primary cells and immunoblot analysis) is desired.</p><p>2. Figure 7. Please describe/show the basal phenotype of Fbn2+/- mice. Also, Fbn2 in Fbn2+/- should be quantified.</p><p>3. Figure 1A. The transcriptional upregulation of Adamts6 in Adamts10 KO mice. I think that this was previously reported, but is the mechanism known? Is it due to the reduced BMP signaling?</p><p>4. The reduced BMP signaling. This was also reported in Adamts10 mutant mice, but has the pathologic significance of the reduced BMP signaling been experimentally tested? Is it just a consequence or does it also contribute to the pathogenesis?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Figure 1A: There appears to be some upregulation of Adamts6 mRNA in Adamts6 mutants in the heart. Is this significant? Compensatory upregulation?</p><p>Figure 1A: The fold increase in Adamts6 mRNA in Adamts10 mutants appears to be modest (lung) or variable (other tissues). Does this increase equate to a difference in protein expression levels? And/or activity?</p><p>Figure 1A: The conclusion that Adamts10 mRNA levels are not altered in Adamts6 mutants is based on 3 samples, 2 of which seem to show a reasonable increase in Adamts10 mRNA in Adamts6 mutants. This raises a possibility that there is reciprocal transcriptional regulation in the limb. Please comment on this, given that the phenotypic analysis here was conducted primarily on limb elements.</p><p>Figure 1: Please indicate numbers of embryos used in the clear skeletal preparation analysis.</p><p>Page 7-Line 174: remove referrals to Figure 1 Suppl. 2 and Figure 1 Suppl 5C-not relevant to the statement about overall lengths of bones.</p><p>Page 8 Lines 182-184. The conclusion that ADAMTS6 and ADAMTS10 exhibit cooperative functions is supported by the phenotypes of single and double mutants. However, it is hard to appreciate how the data presented at this point in the manuscript strongly support the conclusion that transcriptional regulation plays a role. The argument that Adamts10-/- mice are indistinguishable from Adamts6+/-;10-/- mice is based only on length measurements, and there are no data correlating phenotypes with Adamts6 mRNA levels in Adamts10-/- and Adamsts6+/-;10-/- mice.</p><p>Figure 1 Suppl. 6 and Page 8 line 192: Although the expression of Adamts6 in resting and proliferating chondrocytes is clear at E14.5, it is harder to detect at E13.5 in these cells. Perhaps showing a control image would help? Or using arrows to identify the isolated positive cells at this stage?</p><p>Figure 1 Suppl 6 and Page 8 line 195: Arrows/arrowheads should be used to document expression of Adamts6 in tendon/muscle.</p><p>Related to this, do the authors mean the articular surface when referring to Adamts10 expression in the joint interzone?</p><p>Page 9 Lines 208-209. Although the overall levels of Acan are lower in the columnar zone in the double mutant compared to Adamts6-/- mice, there appears to be more Acan staining in the double mutant compared within the resting zone (RZ). Is this a consistent feature? If so, does it reflect premature differentiation of RZ cells in the double mutant compared to Adamts6-/- mice?</p><p>Page 9 Line 211: It looks like <italic>Sox9</italic> expression in the HC is also expanded in all mutants, consistent with delayed ossification.</p><p>Figure 2: Were any histological changes noted in the perichondrium, where Adamts6 and Adamts10 are co-localized?</p><p>Page 9 Line 216: This is just a suggestion. A statement summarizing the key conclusions from Figure 2 would be helpful. It seems that all mutants exhibited evidence of delayed ossification, but Adamts6-/- mice also exhibited a disorganized growth plate accompanied by reduced matrix expression, which was exacerbated in double mutants.</p><p>Figure 3B: It would be best to highlight the posterior femur perichondrium in Adamts6-/- mutants since that is the region used for all other panels in Figure 3A and B. Also, an arrow to inform readers where the perichondrium is will help to discriminate this tissue from the adjacent connective tissue, where staining also appears to be elevated in mutants.</p><p>Page 10 Lines 226-7: The statement is correct, but it seems that there is no expression of fibrillin-1 in perichondrium. The staining appears to be in adjacent connective tissue.</p><p>Figure 5 Suppl. 1: This is not a major point, but it might be helpful to the reader to show the schematics of both the Fbn1- and Fb22-Nt and -Ct fragments to help interpret Figure 5 Suppl. 1C.</p><p>Page 12 Line 297: Check journal policy regarding &quot;data not shown.&quot;</p><p>Page 14 Lines 340-342: It is concluded that ADAMTS6 has a selective impact on fibrillin-2. However, Figure 3 shows little to no Fibrillin-1 staining within the growth plate or perichondrium. Therefore, the selective impact could be due to the much greater abundance of fibrillin-2.</p><p>Page 14 Lines 346-7 and Figure 7 supple 7A. RZ is shown for WT and Adamts6-/- sections, but the CZ is shown for Adamts6-/-;Fn2+/- mice. Show the same zone for all genotypes in the magnifications.</p><p>Page 10 Line 4310-436: I am not convinced that the data document that the observed upregulation of Adamts6 mRNA in the Adamts10 mutant is the reason the latter mutants have a less severe phenotype. Perhaps a protease other than Adamts6 compensates for loss of Adamts10.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.71142.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. The analysis of the skull phenotype, including the cleft palate, is very superficial, incomplete and not properly developed. The authors should consider reporting the correct analysis of the skull in an independent manuscript.</p></disp-quote><p>The phenotype in the skull (Figure 1 —figure supplement 10) illustrates along with the defective ribs, sternum and vertebrae that development of the axial skeleton, and not only the appendicular skeleton, is perturbed in the absence of ADAMTS6, emphasizing a global impact on skeletal development, whose mechanisms are specifically investigated in the appendicular skeleton. The incidence of cleft palate in <italic>Adamts6</italic><sup>-/-</sup> embryos (Figure 8 —figure supplement 2B) is statistically significant and is important to retain, because like long bone defects in <italic>Adamts6</italic><sup>-/-</sup> embryos, it is consistently reversed to normalcy in <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> embryos. Along with the restored normal architecture of the axial and appendicular skeleton, the reversal of cleft palate provides key data supporting reduced fibrillin-2 proteolysis as a primary mechanism of <italic>Adamts6</italic>. We have therefore kept this data as part of the manuscript as a supplemental figure.</p><disp-quote content-type="editor-comment"><p>2. Figure 1, supplement 5 is confusing and of poor quality. The authors should provide a systematic histological analysis at different time points and across all the genotypes. It is sufficient to focus exclusively on one skeletal element and systematically analyze it at different time points and in all the genotypes.</p></disp-quote><p>We thank the reviewer for this comment. We have replaced Figure 1, supplement 5 with new figures (Figure 1 —figure supplement 6, 7, 8, and 9). We also include additional new analysis at E14.5 time point, to demonstrate the role of ADAMTS6 at an earlier landmark in skeletal development when primary ossific nuclei first appear (Figure 3 —figure supplement 2).</p><disp-quote content-type="editor-comment"><p>3. Along those lines, it would be useful to show whether the appearance of hypertrophy is delayed by loss of ADAMTS6, and this phenotype is worsened by concomitant loss of ADAMTS10.</p></disp-quote><p>We thank the reviewer for pointing this out. In early bone development leading up to appearance of primary ossific centers, it does appear that hypertrophy is generally delayed, although chondrocyte hypertrophy is not evident in the developing <italic>Adamts6</italic><sup>-/-</sup> fibula at E16.5, whereas it is evident at 14.5 in the wild type (Figure 1 —figure supplement 8). Once these centers are formed, the hypertrophic zones were comparable as indicated by collagen X staining (Figure 3B).</p><disp-quote content-type="editor-comment"><p>4. Figure 2: Proper quantification of in situ data should be provided.</p><p>8. Figure 7: Please, provide quantification of in situ data.</p></disp-quote><p>The in situ analysis of <italic>Adamts6</italic> and <italic>Adamts10</italic> in wild-type tissues is provided to show the spatial distribution of mRNA of these two genes. We have expanded this dataset to include additional time points to emphasize that both genes are expressed in the perichondrium and peripheral cartilage, developing skeletal muscle, tendon and connective tissue (Figure 2). While we have quantified all immunofluorescence in the manuscript, we have not quantified the in situ data, since it was not intended to be comparative between genotypes.</p><disp-quote content-type="editor-comment"><p>5. Figure 3: As above, proper quantification of immunofluorescence data should be provided.</p><p>6. Figure 4: Please, provide quantification.</p><p>7. Figure 4 , supplement 1: Please, provide quantification.</p></disp-quote><p>As recommended, all immunofluorescence staining has now been quantified and data displayed in bar graphs in Figure Supplements corresponding to figures where immunofluorescence is shown.</p><disp-quote content-type="editor-comment"><p>9. It is critical to histologically document whether haploinsufficiency for fibrillin2 prevents the delay of endochondral bone development secondary to loss of ADAMTS6.</p></disp-quote><p>We agree that this is an essential point. As Figure 8B shows, there is comparable endochondral ossification in the <italic>Adamts6</italic><sup>-/-</sup>;<italic>Fbn2</italic><sup>+/-</sup> hindlimbs as the wild type, and distinctly more than in <italic>Adamts6</italic><sup>-/-</sup> mutant limbs in all bones, specifically in the fibula, for example, where it was most drastically reduced. In addition, histologically, proteoglycan content and <italic>Sox9</italic> staining were significantly restored toward normal based on immunofluorescence staining of sections (Figure 8D).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Figure 3 and Figure 4. Quantification of Fbn2 abundance (e.g. using primary cells and immunoblot analysis) is desired.</p></disp-quote><p>We have quantified all primary cell and immunoblot data (Figure 4 —figure supplement 1A, Figure 5 and Figure 5 —figure supplement 1).</p><disp-quote content-type="editor-comment"><p>2. Figure 7. Please describe/show the basal phenotype of Fbn2+/- mice. Also, Fbn2 in Fbn2+/- should be quantified.</p></disp-quote><p>In response, this has been addressed experimentally (Figure 8 —figure supplement 3 and 4).</p><disp-quote content-type="editor-comment"><p>3. Figure 1A. The transcriptional upregulation of Adamts6 in Adamts10 KO mice. I think that this was previously reported, but is the mechanism known? Is it due to the reduced BMP signaling?</p></disp-quote><p>The transcriptional upregulation of <italic>Adamts6</italic> (Figure 1A)was not previously shown in <italic>Adamts10</italic><sup>-/-</sup> mice or in any other in vivo system; prior work showed a similar upregulation in vitro in an ocular cell line (ARPE-19) upon <italic>Adamts6</italic> knockdown (Cain et al., <italic>Sci Rep.</italic> 2016, PMID 27779234), but not in vivo. Reciprocal transcriptional upregulation of <italic>Adamts10</italic> in <italic>Adamts6</italic><sup>-/-</sup> mice is also shown in our study, which is a further novel finding. BMPs are not known to have a role in this process and we did not specifically investigate its basis.</p><disp-quote content-type="editor-comment"><p>4. The reduced BMP signaling. This was also reported in Adamts10 mutant mice, but has the pathologic significance of the reduced BMP signaling been experimentally tested? Is it just a consequence or does it also contribute to the pathogenesis?</p></disp-quote><p>The previous report showed that BMP signaling was reduced in fibroblasts isolated from an <italic>Adamts10</italic> genetic mutant disease model, but not in mouse tissues/skeleton (Mularczyk et al., Human Mol Genet, 2018, PMID 30060141). However, the mechanism of the reduction was not explored at all nor was it ever previously analyzed in <italic>Adamts6</italic><sup>-/-</sup> mutants. We show here that the reduction of BMP signaling (as shown by reduced pSMAD1/5/8 signaling both in tissue sections and via western blot analysis) in <italic>Adamts6</italic><sup>-/-</sup> cartilage is due to the increase of fibrillin-2 and that, in turn, results in sequestration of GDF5 (Figure 9, Figure 10, Figure 10 —figure supplement 1 and Figure 11). Upon introduction of <italic>Fbn2</italic> haploinsufficiency, the reduced BMP signaling in <italic>Adamts6</italic><sup>-/-</sup> mutants was clearly mitigated (Figure 9A-D).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Figure 1A: There appears to be some upregulation of Adamts6 mRNA in Adamts6 mutants in the heart. Is this significant? Compensatory upregulation?</p><p>Figure 1A: The fold increase in Adamts6 mRNA in Adamts10 mutants appears to be modest (lung) or variable (other tissues). Does this increase equate to a difference in protein expression levels? And/or activity?</p><p>Figure 1A: The conclusion that Adamts10 mRNA levels are not altered in Adamts6 mutants is based on 3 samples, 2 of which seem to show a reasonable increase in Adamts10 mRNA in Adamts6 mutants. This raises a possibility that there is reciprocal transcriptional regulation in the limb. Please comment on this, given that the phenotypic analysis here was conducted primarily on limb elements.</p></disp-quote><p>Thank you for your comments regarding the qPCR analysis of <italic>Adamts6</italic> and <italic>Adamts10</italic> in the mutant embryo tissues. We originally had n=3 for each genotype and tissue. We have subsequently doubled this to n=6 to address the reviewer comment. In this revised dataset, there is decreased <italic>Adamts6</italic> mRNA in <italic>Adamts6</italic><sup>-/-</sup> limbs and lungs, but not the heart. The fold increase in <italic>Adamts6</italic> mRNA in <italic>Adamts10</italic><sup>-/-</sup> embryos is 2-, 4- and 2.5-fold in the limb, heart and lung, respectively. This suggests that the ADAMTS6 upregulation could provide a potential albeit partial compensatory mechanism in <italic>Adamts10</italic> mutant mice. We also observed compensatory upregulation of <italic>Adamts10</italic> mRNA in <italic>Adamts6</italic><sup>-/-</sup> mice. We conclude, as the reviewer suggested, that there is reciprocal transcriptional regulation in the limb. In addition, we quantified <italic>Adamts17</italic> and <italic>Adamts19</italic> mRNAs since mutations of ADAMTS17, like those in ADAMTS10, can cause Weill-Marchesani syndrome (Morales et al., PMID19836009). ADAMTS19 was included as the closest homolog of ADAMTS17. There was no alteration of either <italic>Adamts17</italic> or <italic>Adamts19</italic> mRNA levels in the mutant tissues, suggesting specificity of the ADAMTS6 and ADAMTS10 response in relation to each other (updated Figure 1A).</p><disp-quote content-type="editor-comment"><p>Figure 1: Please indicate numbers of embryos used in the clear skeletal preparation analysis.</p></disp-quote><p>The n of each genotype is shown in Figure 1 —figure supplement 4.</p><disp-quote content-type="editor-comment"><p>Page 7-Line 174: remove referrals to Figure 1 Suppl. 2 and Figure 1 Suppl 5C-not relevant to the statement about overall lengths of bones.</p></disp-quote><p>Thank you for this comment. This has been revised as suggested.</p><disp-quote content-type="editor-comment"><p>Page 8 Lines 182-184. The conclusion that ADAMTS6 and ADAMTS10 exhibit cooperative functions is supported by the phenotypes of single and double mutants. However, it is hard to appreciate how the data presented at this point in the manuscript strongly support the conclusion that transcriptional regulation plays a role. The argument that Adamts10-/- mice are indistinguishable from Adamts6+/-;10-/- mice is based only on length measurements, and there are no data correlating phenotypes with Adamts6 mRNA levels in Adamts10-/- and Adamsts6+/-;10-/- mice.</p></disp-quote><p>We suggest that ADAMTS6 and ADAMTS10 exhibit cooperative functions due to the more drastic phenotype in the double-knockout embryo as compared to either single knockout embryos (Figure 1B). The observed reciprocal transcriptional regulation of these homologous proteases (Figure 1A) could have a role in masking the individual phenotype, but we agree with the reviewer that this remains open to interpretation. We have softened this point accordingly to state that although transcriptional adaptation is observed and could mask the phenotypes of individual gene mutants, its precise impact remains unclear.</p><disp-quote content-type="editor-comment"><p>Figure 1 Suppl. 6 and Page 8 line 192: Although the expression of Adamts6 in resting and proliferating chondrocytes is clear at E14.5, it is harder to detect at E13.5 in these cells. Perhaps showing a control image would help? Or using arrows to identify the isolated positive cells at this stage?</p></disp-quote><p>Thank you for the suggestion. We now show expression at E13.5 and E14.5 at higher magnification for both <italic>Adamts6</italic> and <italic>Adamts10</italic> throughout the musculoskeletal system (Figure 2). The recommended control for RNAscope (<italic>DapB</italic> probe) did not give a signal, but is not illustrated.</p><disp-quote content-type="editor-comment"><p>Figure 1 Suppl 6 and Page 8 line 195: Arrows/arrowheads should be used to document expression of Adamts6 in tendon/muscle.</p><p>Related to this, do the authors mean the articular surface when referring to Adamts10 expression in the joint interzone?</p></disp-quote><p>As suggested, we have added specific annotation of tendons and muscle in in situ panels (Figure 2). <italic>Adamts10</italic> is broadly expressed throughout the musculoskeletal elements, which include the joint interzone as well as the surrounding tissues. At this stage, a synovial cavity is not apparent and we designated the inter-cartilage mesenchyme as constituting the joint interzone.</p><disp-quote content-type="editor-comment"><p>Page 9 Lines 208-209. Although the overall levels of Acan are lower in the columnar zone in the double mutant compared to Adamts6-/- mice, there appears to be more Acan staining in the double mutant compared within the resting zone (RZ). Is this a consistent feature? If so, does it reflect premature differentiation of RZ cells in the double mutant compared to Adamts6-/- mice?</p></disp-quote><p>There is an overall reduction of Acan both in <italic>the Adamts6</italic><sup>-/-</sup> and the <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> growth plates (Figure 3 —figure supplement 3 shows no statistical difference between the two groups).</p><disp-quote content-type="editor-comment"><p>Page 9 Line 211: It looks like Sox9 expression in the HC is also expanded in all mutants, consistent with delayed ossification.</p></disp-quote><p>We thank the reviewer for noting this. <italic>Sox9</italic> is not only expressed in the early chondrocytes of the resting zone, but also in hypertrophic chondrocytes as pointed out, but we quantified it in the reserve and proliferative zones where the matrix was greatest.</p><disp-quote content-type="editor-comment"><p>Figure 2: Were any histological changes noted in the perichondrium, where Adamts6 and Adamts10 are co-localized?</p></disp-quote><p>In response to this comment, we include data showing altered perichondrium ECM (more collagen staining) using RGB trichrome (Figure 3 —figure supplement 1). In addition, as shown with fibrillin-2 and MAGP-1 staining, there is an increase of both molecules in perichondrial ECM (Figure 4, Figure 10).</p><disp-quote content-type="editor-comment"><p>Page 9 Line 216: This is just a suggestion. A statement summarizing the key conclusions from Figure 2 would be helpful. It seems that all mutants exhibited evidence of delayed ossification, but Adamts6-/- mice also exhibited a disorganized growth plate accompanied by reduced matrix expression, which was exacerbated in double mutants.</p></disp-quote><p>We agree and have added a concluding sentence in this section (top of pg 10), stating “These findings therefore indicate a substantial disruption of the <italic>Adamts6</italic>-mutant chondrocyte phenotype, which was exacerbated in the <italic>Adamts6</italic><sup>-/-</sup>;<italic>Adamts10</italic><sup>-/-</sup> mutants”.</p><disp-quote content-type="editor-comment"><p>Figure 3B: It would be best to highlight the posterior femur perichondrium in Adamts6-/- mutants since that is the region used for all other panels in Figure 3A and B. Also, an arrow to inform readers where the perichondrium is will help to discriminate this tissue from the adjacent connective tissue, where staining also appears to be elevated in mutants.</p></disp-quote><p>We have updated the figure (now Figure 4) to indicate the posterior perichondrium.</p><disp-quote content-type="editor-comment"><p>Page 10 Lines 226-7: The statement is correct, but it seems that there is no expression of fibrillin-1 in perichondrium. The staining appears to be in adjacent connective tissue.</p></disp-quote><p>We thank the reviewer for pointing this out. We agree, the staining is primarily in the adjacent connective tissue, which is unchanged in the mutants as compared to the control (Figure 4C).</p><disp-quote content-type="editor-comment"><p>Figure 5 Suppl. 1: This is not a major point, but it might be helpful to the reader to show the schematics of both the Fbn1- and Fb22-Nt and -Ct fragments to help interpret Figure 5 Suppl. 1C.</p></disp-quote><p>We have updated the figures accordingly (Figure 6A and Figure 6 —figure supplement 1A).</p><disp-quote content-type="editor-comment"><p>Page 12 Line 297: Check journal policy regarding &quot;data not shown.&quot;</p></disp-quote><p>As per journal policy, we have deleted all instances of “data not shown” from the manuscript.</p><disp-quote content-type="editor-comment"><p>Page 14 Lines 340-342: It is concluded that ADAMTS6 has a selective impact on fibrillin-2. However, Figure 3 shows little to no Fibrillin-1 staining within the growth plate or perichondrium. Therefore, the selective impact could be due to the much greater abundance of fibrillin-2.</p></disp-quote><p>We thank the reviewer for this observation and agree. The impact on fibrillin-2 is greater, consistent with this isoform being more abundant in the embryonic period (Figure 4 and quantified in Figure 4 —figure supplement 1A) and our conclusion that a major function of ADAMTS6 is to control/reduce the fibrillin-2 microfibril burden as development progresses toward postnatal life.</p><disp-quote content-type="editor-comment"><p>Page 14 Lines 346-7 and Figure 7 supple 7A. RZ is shown for WT and Adamts6-/- sections, but the CZ is shown for Adamts6-/-;Fn2+/- mice. Show the same zone for all genotypes in the magnifications.</p></disp-quote><p>Thank you for pointing this out. The figure (now Figure 8C) is revised accordingly.</p><disp-quote content-type="editor-comment"><p>Page 10 Line 4310-436: I am not convinced that the data document that the observed upregulation of Adamts6 mRNA in the Adamts10 mutant is the reason the latter mutants have a less severe phenotype. Perhaps a protease other than Adamts6 compensates for loss of Adamts10.</p></disp-quote><p>We agree that the viewer’s interpretation is justified and have revised the text to provide a more nuanced interpretation. ADAMTS10 is weakly activated by furin and promotes fibrillin-1 microfibril assembly by cultured fibroblasts, as demonstrated by us and others (Kutz et al., J Biol Chem, 2011, PMID 21402694; Mularczyk et al., Human Mol Genet, 2018, PMID 30060141). It cleaves fibrillin-2, but only weakly cleaves fibrillin-1 and only when activated by optimizing the furin cleavage site (Kutz et al., J Biol Chem, 2011, PMID 21402694;Wang et al., Matrix Biology 2019, PMID 30201140). Hence, ADAMTS10 differs from ADAMTS6 in these important characteristics, and a relevant experimental observation highlighted in the present work is that both fibrillin-1 and fibrillin-2 microfibrils are absent in the presence of ADAMTS6 (Figure 5). In response to the reviewers second comment, we determined mRNA levels of homologous proteases <italic>Adamts17</italic> and <italic>Adamts19</italic> and observed no change in expression of either in the mutants (Figure 1A).</p></body></sub-article></article>